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1. Abstract 
 
B cell precursors Acute Lymphoblastic Leukemia (BCP-ALL) is a tumor characterized by the 
malignant expansion of B cell progenitors and it is the most common childhood cancer. About 30% 
of BCP-ALL cases are characterized by mutations, deletions or translocations of the PAX5 gene. 
Among PAX5 translocations, the most recurrent is t(9;12) which determines the generation of 
PAX5/ETV6 fusion gene. The PAX5 transcription factor is essential for B cell lineage commitment 
and differentiation. PAX5 fulfills its function mainly through the activation of B lineage-specific 
genes and the repression of inappropriate ones. ETV6 transcription factor is specifically required for 
adult hematopoiesis in mice. Moreover, ETV6 accelerates erythroid differentiation of cell lines and 
it stimulates hemoglobin synthesis in adult mice. PAX5/ETV6 is able to down-regulate the expression 
of some PAX5-activated-genes, as well as to up-regulate some PAX5-repressed-genes. Accordingly, 
PAX5/ETV6 caused the alteration of B cell differentiation and conferred survival advantages to 
mouse B cell precursors in vitro. The acquisition of survival advantages by PAX5/ETV6 expressing 
cells is due to the activation of the Lck-STAT5 pathway leading to the upregulation of STAT5 
effectors Ccnd2 and cMyc. When we started this project very little was known about the conservation 
of pax5 and etv6 roles in zebrafish hematopoiesis. We thus analyzed their expression pattern and we 
found that these genes are expressed in several hematopoietic tissues. Indeed, pax5 is expressed in 
pancreas, which has been proposed to be a transient embryonic site of B cell lymphopoiesis in 
zebrafish. pax5 knockdown caused the alteration of the expression of several B cell markers. 
Otherwise, etv6 is expressed in tissues related to both primitive and definitive hematopoiesis. etv6 
loss of function determined the reduction of primitive mature erythrocytes and we found that this 
alteration is due to the defective differentiation of primitive erythrocytes. Moreover, we tried to shed 
light into the mechanism through which etv6 regulates primitive erythrocytes maturation. 
Interestingly, we found that etv6 is a potential modulator of Notch signaling in primitive erythrocytes. 
Furthermore, etv6 is involved, directly or indirectly, in the repression of klf1, klf3, klf6a and klf17 
genes, which are essential for primitive erythrocytes maturation. Overall, our findings suggest that 
the roles of pax5 and etv6 in hematopoiesis could be, at least in part, conserved in zebrafish. 
Interestingly, etv6 knockdown caused the alteration of the expression of some B cell markers which 
are impaired also by pax5 loss of function, thus, we investigated if the contemporary pax5 and etv6 
knock-down could cooperate to alter the expression of these genes. However, the coinjection of pax5 
and etv6 morpholinos did not cause significant alteration of igh and cd79a, thus excluding a 
possible cooperation between pax5 and etv6 in the regulation of their expression. Finally, we 
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transiently expressed PAX5/ETV6 in zebrafish embryos and, despite it did not caused the deregulation 
of B cell markers expression, this aberrant gene is able to activate the same pathway which is altered 
in vitro, inducing the phosphorylation of Lck and Stat5 proteins as well as the upregulation of Stat5 
effectors, suggesting that zebrafish could be a suitable model to study BCP-ALL related to 
PAX5/ETV6 fusion gene. 
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2. State of the Art 
 
Acute Lymphoblastic Leukemia (ALL) is a tumor characterized by the malignant expansion of 
lymphoid progenitor cells. The 85% of ALL cases are caused by the proliferation of B cell precursors 
and this subtype of leukemia is indeed called B cell precursors ALL (BCP-ALL) (Guzman and 
Jordan, 2004). BCP-ALL is the most common childhood cancer and the main cause of death related 
to tumor in children and young adults (Mullighan, 2012). About 30% of BCP-ALL cases are 
characterized by mutations, deletions or translocations of PAX5 gene. Among several translocations 
involving different partner genes, the most recurrent is t(9;12) that causes the fusion of PAX5 with 
ETV6 gene (Mullighan et al., 2007; An et al., 2008; Kawamata et al.,2008). Despite several genetic 
lesions involving both PAX5 and ETV6 have been identified, we are fare from the complete 
understanding of their role in the pathogenesis of leukemia. Moreover, the information currently 
available derive mainly from in vitro models. However, these models are obviously unable to fully 
represent the complexity of animal organisms and is thus necessary to reproduce human pathologies 
in vivo for two purposes: gain new insights in the molecular mechanisms underlying diseases to 
discover novel therapeutic targets and perform drug screenings to find new pharmacological 
treatments. 
Zebrafish has emerged as an excellent model organism because it allows to link genetic and molecular 
studies to morphological whole-organism analysis and it offers several advantages compared to other 
vertebrate model systems. The external fertilization and development, together with the optical clarity 
of the embryos allow in vivo and ex vivo easy visualization of embryonic development and 
manipulation of zebrafish embryos. Moreover, the small size of the zebrafish embryo ensures a 
sufficient supply of oxygen by passive diffusion to survive and develop for several days in condition 
of absence of blood circulation. Zebrafish resulted to be particularly suitable for the study of 
hematopoiesis and hematopoietic disorders affecting humans, because the developmental processes 
and genetic programs of hematopoiesis, as well as the main blood cell types, are highly conserved, 
despite some differences do exist (Lieschke and Currie, 2007; Paik and Zon, 2010; Jing and Zon, 
2011). Zebrafish models of human leukemia caused by ETV6/RUNX1 and ETV6/JAK2 gene fusions 
have already been generated and they were found to be useful tools to gain insights into the leukemic 
process in vivo and for the identification of new potential therapeutic targets (Sabaawy et al., 2006; 
Onnebo et al., 2012). 
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The main aims of this project are to test if the roles of pax5 and etv6 in hematopoiesis are conserved 
in zebrafish and to verify if zebrafish could be a useful model to reproduce PAX5/ETV6 related 
leukemia. 
 
 
2.1. Hematopoiesis 
 
Hematopoiesis is the process by which blood cells are formed and occurs during embryonic 
development and throughout adulthood to produce and renew the blood cellular elements. the 
developmental processes and genetic programs of hematopoiesis are highly conserved between fish 
and mammals, although some differences do exist. All vertebrates, included zebrafish, are 
characterized by two main wave of hematopoiesis. During the first one, called primitive wave, 
transient precursors give rise only to erythrocytes and macrophages during early embryonic 
development; during the second one, called definitive wave, multipotent hematopoietic stem cells 
(HSCs) gives rise to all blood cell lineages (Fig.1; Galloway and Zon, 2003). 
 
 
 
Figure 1: Primitive and definitive waves in zebrafish. Some of the most important genes are represented. 
HSC: hematopoietic stem cell (modified from Jagannathan-Bogdan and Zon, 2013). 
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The primary purpose of the primitive wave is to produce red blood cells that can facilitate tissue 
oxygenation as the embryo undergoes rapid growth (Orkin and Zon, 2008). In mammals and birds, 
primitive hematopoiesis occurs in the blood islands located in the extra-embryonic yolk sac, whereas 
in zebrafish primitive blood cells originate in intra-embryonic structures (Detrich et al., 1995; Palis 
et al., 2001). Primitive myelopoiesis takes place in the anterior lateral mesoderm (ALM), located in 
the rostral portion of the embryo, and mainly produces macrophages (Fig. 2; Herbomel et al., 1999). 
Primitive erythroid precursors originate from two bilateral stripes in the posterior lateral plate 
mesoderm (PLM) around 5 somite stage (Fig. 2; Detrich et al., 1995). Later, around 18 somite stage, 
these precursors migrate towards the midline to give rise to the equivalent of the mammalian blood 
islands, the intermediate cell mass (ICM). Within the ICM, erythroid progenitors differentiate in 
proerytrhroblasts that enter the circulation at 24-26 hpf (hours post fertilization; Fig. 2; Detrich et al., 
1995). These cells continue to mature in circulation and are the only circulating red cell population 
through 4dpf (days post fertilization), but can persist until at least 7 dpf (Weinstein et al., 1996; Chen 
and Zon, 2009). Erythrocytes differentiation consists in cytological changes in cell size, in nuclear 
shape and in cytoplasm staining. The most immature cells are big round-shaped, have a large and 
open nucleus and a more basophilic cytoplasm (Ransom et al., 1996). Mature erythrocytes are rugby-
ball shaped and smaller than precursors, the nucleus is more condensed and the cytoplasm is 
acidophilic (Ransom et al., 1996). All zebrafish mature erythrocytes, both primitive and definitive, 
are nucleated, while mammalian erythrocytes retain their nucleus in the primitive wave but not in the 
adult (Chen and Zon, 2009). These cytological changes are accompanied by ‘maturational’ globin 
switching as erythrocytes differentiate. The first switch take place between 24 hpf and 48 hpf, and it 
is characterized by the sharp decrease of hemoglobin beta embryonic 3 (hbbe3) gene and the 
concomitant increase of hbbe1 gene. The second switch that establishes the adult globin expression 
begins around 22 dpf leading to the increasing expression of the nearly exclusively adult globins a1 
and a1 by 32 dpf (Ganis et al., 2012). 
Primitive hematopoieis is largely regulated by gata1, the master regulator gene of erythrocyte 
development, and pu.1, crucial for myeloid fate acquisition (Scott et al., 1994; Cantor et al., 2002). 
These two transcription factors exhibit a cross-inhibitory relationship to regulate erythrocyte and 
myeloid fates. Other important transcriptional regulators of erythropoiesis are the members of the 
Kruppel-like transcription factor family, that are known to activate erythroid-specific genes (Palis, 
2014). In mammals KLF1 primarily regulates the adult β GLOBIN gene but also the expression of 
multiple erythroid-specific genes, whereas in zebrafish it is known to be involved in primitive 
erythropoiesis regulating globin gene (Donze et al., 1995; Hodge et al., 2006; Pilon et al., 2006; 
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Fu et al., 2009). Moreover, in zebrafish klf3 and klf6a are essential for erythroid cell differentiation 
and maturation (Xue et al., 2015). Also klf17, previously reported as klf4, is essential for primitive 
erythrocytes maturation through the activation of genes involved in heme synthesis and embryonic 
globin genes. Specifically, klf17 binds to the embryonic -like globin gene promoters and klf17 loss 
of function causes the downregulation of hbbe3 gene (Gardiner et al., 2007; Xue et al., 2015). 
 
 
Figure 2: Sites of hematopoiesis during zebrafish development. Sites of primitive hematopoiesis: anterior 
lateral mesoderm (ALM) and posterior lateral mesoderm (PLM); intermediate cell mass (ICM), Sites of 
definitive hematopoiesis: aorta-gonad-mesonephros region (AGM); caudal hemtopoietic tissue (CHT); kidney; 
thymus. The corresponding developmental stages are shown. Some of the most important genes are 
represented. HSC: hematopoietic stem cell (modified from Paik and Zon, 2010; Jagannathan-Bogdan and 
Zon, 2013) 
 
 
Definitive hematopoiesis provides long-term multipotent HSCs with self-renewal property, which are 
able to differentiate in erythroid, myeloid and lymphoid lineages throughout the life of the organism. 
In mammals HSCs originate from the aorta-gonad-mesonephros region (AGM) and they migrate to 
the fetal liver and then to the bone marrow, which is the location for HSCs in adults (Fig. 2; Cumano 
and Godin, 2007). In zebrafish, the ventral wall of the dorsal aorta has been identified as the analogous 
of this AGM region (Murayama et al., 2006; Kissa et al., 2008). Starting from about 30 hpf, HSCs 
emerge from the ventral wall of the dorsal aorta, they enter circulation through the axial vein and 
migrate to the region of the caudal hematopoietic tissue (CHT) in the posterior region of the tail (Fig. 
2; Bertrand et al., 2010; Kissa and Herbomel, 2010). Around 3 dpf, HSCs leave the CHT to colonize 
the organs that will be the sites of adult hematopoiesis. HSCs colonize first the thymus, the site of T 
cell lymphopoiesis, and one day later the kidney marrow, the site of hematopoiesis of all the other 
blood cell lineages, which is the analogous of the bone marrow in mammals (Fig. 2; Murayama et 
al., 2006; Jin et al., 2007; Bertrand et al., 2008; Kissa et al., 2008).  
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2.1.1. B cell development 
The pluripotent HSCs with its self-renewal potential regenerates all blood cell types throughout life 
by differentiating to progenitor cells with gradually restricted developmental potential generating a 
large number of specialized cells. One of the earliest event in hematopoiesis is the differentiation of 
HSCs in the multipotent progenitor (MPP) which can undergoes commitment to either the lymphoid 
or erythro-myeloid lineages, resulting in the formation of the early lymphoid progenitors (ELP) or 
common myeloid progenitors (CMP Fig. 4). ELPs start to express the recombination activating gene 
1 (rag1) and rag2 and initiate rearrangements at the immunoglobulin heavy chain (IgH) locus. The 
ELP can further differentiate into thymic precursors of the T-cell lineage or into bone-marrow 
common lymphoid progenitors (CLP; Fig. 4). The CLPs can generate B cells, T cells, dendritic cells 
and natural killer cells. In mammals, the entry of CLPs in the B cell differentiation pathway and the 
transition to the pro-B stage is characterized by the expression of the B cell marker B220 (Fig.4). 
Subsequently, CD19 is expressed and the IgH diversity (DH)-to-joining (JH) gene segment 
rearrangement is completed, identifying pre-BI cells. The IgH locus then continues to rearrange its 
variable (VH) region gene segments until productive VH–DJH alleles are generated in large pre-BII 
cells. These cells expose the product of the rearranged IgH gene at the cell surface, where it assembles 
with the co-receptors molecules Ig, encoded by the Cd79a gene, and Ig, encoded by the Cd79b 
gene, to form the pre-B-cell receptor (pre-BCR; Fig. 3, 4). 
 
Figure 3: Schematic representation of a pre-B cell exposing the pre-BCR. (Modified from Herzog et 
al.,2009). 
 
 
The expression of the pre-BCR is a crucial check-point in early B-cell development, and its signaling 
stimulates a proliferative clonal expansion of large pre-BII cells, which is followed by the 
rearrangements of immunoglobulin light-chain genes. Once an immature B cell expresses IgM on its 
surface, it emigrates from the bone marrow to peripheral lymphoid organs, such as the spleen, where 
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they further differentiate through several transitional stages. After the appropriate selection, 
transitional B cell can differentiate into mature B cells. About 10% of mature splenic B cells are 
marginal zone B cells. They are strategically positioned at the blood-lymphoid tissue interface, where 
they can initiate a fast and vigorous antibody response to blood pathogens. Transitional, follicular and 
even memory B cells can give rise to marginal-zone B cells, responsible for antibody response to 
blood pathogens, and/or be recruited into this compartment. In mice, most mature B cells are follicular 
B cells. These cells are mainly responsible for generating humoral immune responses to protein 
antigens. With the help of T cells, they form germinal centres. Germinal-centre B cells proliferate 
rapidly, undergo somatic hypermutation of their immunoglobulin variable gene segments and 
undergo isotype-switch recombination of immunoglobulin genes. Subsequently, germinal centres 
slowly vanish, and memory B cells and effector plasma cells are generated (Busslinger, 2004; 
Matthias and Rolink, 2005). 
 
 
 
Figure 4: Schematic representation of B cell development. The main markers of the different maturation 
stages are indicated. Hematopoietic stem cell (HSC); multipotential progenitor (MPP); early lymphoid 
progenitor (ELP); common lymphoid progenitor (CLP); common myeloid progenitor (CMP); early T 
progenitor (ETP) (Fazio et al.,2011). 
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During early B cell development, three transcription factors have been found to be essential for the 
differentiation of CLPs into specified pro-B cells: E2A, EBF1 and PAX5. Absence of any of these 
factors leads to an early block in B cell development at the pro-B cell or pre-B cell stage. These three 
factors seem to work in collaboration, and together, they form a master control switch for engaging 
B cell differentiation (Matthias and Rolink, 2005). E2A and EBF1 are considered primary B cell fate 
determinants and coordinately activate the expression of B cell specific genes, however, they are not 
sufficient to commit B cell progenitor to B cell lineage (Fuxa and Skok, 2007).  
Very little is known about B cell lymphopoiesis during zebrafish development, in fact, Only Danilova 
and Steiner (2002) suggested that the pancreas could be a transient site of B cell lymphopoiesis in 
zebrafish. This hypothesis is based on the expression of rag1 at 4 dpf and igh from 10 dpf in the 
pancreas. Subsequently, B cell lymphopoiesis moves to the head kidney at about 2 weeks post 
fertilization (wpf), as suggested by rag1 expression in this organ. Accordingly, ighexpression has 
been observed in the kidney at 19 dpf (Danilova and Steiner, 2002; Zapata et al., 2006). 
 
 
2.2. Acute Lymphoblastic Leukemia 
 
Acute Lymphoblastic Leukemia (ALL) is a biologically heterogeneous disorder characterized by the 
malignant proliferation of lymphoblasts, the lymphoid progenitor cells, which are not able to properly 
differentiate (Guzman and Jordan, 2004). The disease is characterized by the clonal proliferation and 
accumulation of malignant blast cells in the bone marrow and peripheral blood (Harrison, 2001). An 
estimated 6000 new cases of ALL are diagnosed every year in the USA, patients are both adults and 
children but ALL incidence peaks between 2 and 5 years of age (Inaba et al., 2013). ALL is mainly 
caused by the acquisition of mutations in somatic cells and only less than 5% of the cases are 
associated with inherited genetic syndromes, such as Down’s syndrome (Pui et al., 2008; Inaba et al., 
2013). The most of childhood cases of ALL show extended chromosomal alterations such as: 
hyperdiploidy; hypodiploidy; recurring translocations leading to aberrant gene fusions such as BCR-
ABL1 and ETV6-RUNX1; rearrangements of MLL with a wide range of partner genes and 
rearrangements of MYC (Inaba et al., 2013). Several of this genetic lesions disrupt genes involved in 
hematopoiesis (RUNX1, ETV6), activate oncogenes (MYC) and constitutively activate tyrosine 
kinases (ABL1). However, many of these alterations alone are not sufficient to induce leukemia in 
experimental models, suggesting that other genetic lesions cooperate to oncogenic transformation; 
for example, pathologies related to ETV6-RUNX1 and BCR-ABL1 have between six and eight 
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additional genetic alterations (Fig. 5; Greaves et al., 2003; Mullighan et al., 2007; Pui et al., 2008; 
Inaba et al., 2013). Several of these cooperating mutated genes encode tumor suppressors, cell cycle 
and lymphoid development regulators and are responsible for the establishment of the specific 
leukemic clone. The most frequently mutated genes, affecting about 40% of BCP-ALL cases, are 
transcription factors involved in B cell development such as PAX5, E2A, EBF1 and IKAROS that can 
be altered by various mechanisms including deletions, amplifications, sequence mutations and 
translocations (Fig. 5; Mullighan et al., 2007; Pui et al., 2008; Inaba et al., 2013). In some case these 
transcription factors are functionally normal but their expression is deregulated leading to abnormal 
proliferation and block of differentiation of lymphoid progenitors. In other case the chromosomal 
translocations generate chimeric transcription factors which can alter the expression of normal targets 
of the endogenous proteins and cause the recognition of genes different than those recognized by wild 
type factors (Mullighan et al., 2007; O'Neil and Look, 2007; Pui et al., 2008; Inaba et al., 2013). 
 
 
Figure 5: Proposed model for the role of genetic alterations in BCP-ALL. (Mullighan, 2012). 
 
 
Overall, these findings suggested a multistep model of leukemia pathogenesis in which sequential 
mutational events are accumulated starting from the initial alteration, usually acquired in utero, 
through the largely covert evolution to overt disease, that can occur even several years later after the 
acquisition of the initial lesion (Fig. 5; Greaves et al., 2003; Mullighan, 2012; Inaba et al., 2013). 
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Now it is commonly thoughts that acute lymphoblastic leukaemia, like cancer in general, probably 
arises from interactions between exogenous or endogenous exposures, genetic (inherited) 
susceptibility, and chance. The challenge is to identify the relevant exposures and inherited genetic 
variants and decipher their roles in leukemia pathogenesis (Fig. 5; Greaves et al., 2003; Mullighan, 
2012; Inaba et al., 2013). 
About 15% of ALL cases are a result of the proliferation of T cell precursors, whereas the remaining 
85% of the cases are caused by the expansion of B cell precursors (Guzman and Jordan, 2004). The 
PAX5 gene is the most frequent target of somatic mutations in BCP-ALL cases. Specifically, about 
30% of BCP-ALL cases are characterized by mutations, deletions or translocations of PAX5; the most 
recurrent among PAX5 translocations is t(9;12), that causes the fusion of PAX5 with ETV6 gene 
(Cazzaniga et al., 2001; Mullighan et al., 2007). 
 
 
2.3. PAX5 
 
2.3.1. PAX5 gene and encoded protein structure 
PAX5 (Paired box domain 5) belongs to the Paired Box family of transcription factors which 
comprises 9 genes in mammals, 15 in zebrafish and 4 in the basal chordates such as the amphioxus 
(Stapleton et al., 1993; Paixao-Cortes et al., 2013). This diversity in the number of PAX genes across 
chordates is due to three event of whole genome duplication, two occurred during early vertebrate 
evolution and one teleost-specific, and other additional partial duplication events (Amores et al., 
1998; Meyer and Van de Peer, 2005; Van de Peer et al., 2009; Paixao-Cortes et al., 2013). Human 
PAX5 is located on the chromosome 9 and has 10 exons which can give rise to more than 10 splicing 
variants in both normal and cancer cells; it has been suggested that alternative splicing could be an 
important mechanism of regulation of PAX5 activity (Zwollo et al., 1997; Borson et al., 2002; 
Arseneau et al., 2009). Zebrafish pax5 is mapped on chromosome 1 and has 11 exons; two alternative 
splicing variants have been identified so far, the first is the full length coding sequence whereas the 
second one lacks the exon 2 and has a partial Paired Box DNA binding domain (Pfeffer et al., 1998; 
Kwak et al., 2006). 
PAX proteins can be subdivided into four subfamilies based on the similarity of the Paired Box 
domain sequence and the presence of additional functional domains; According to these criteria, 
PAX5 is grouped into the PAX2/5/8 subfamily (Pfeffer et al., 1998; Paixao-Cortes et al., 2015). 
Indeed, the defining feature of PAX5 is the Paired Box DNA binding domain (PD), located at the N-
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terminal portion of the protein, which consists of an N-terminal and a C-terminal subdomain (Fig. 6; 
Czerny et al., 1993). Each subdomain is composed of three helices organized in a helix-turn-helix 
motif and independently binds to a distinct half-site of the PAX5 recognition sequence in adjacent 
major grooves of the DNA helix (Garvie et al., 2001). Each half-site independently contributes to the 
overall affinity of a given binding site and this characteristic of the PD domain is responsible for its 
degenerate consensus sequence (Fig. 6; Czerny et al., 1993; Cobaleda et al., 2007). The 
transcriptional activity of PAX5 is regulated by the interaction of several partners with central and C-
terminal domains of the protein. Transactivation activity of PAX5 is mediated by the partial 
Homeodomain (HD) and the Transactivation domain (TAD) (Fig. 6; Cobaleda et al., 2007). The 
partial HD of PAX5 interact with the TATA-binding protein of the basal transcription machinery and 
the Retinoblastoma protein, while the TAD modulates transcription probably through the interaction 
with histone acetyltranferases such as the Creb binding protein or SAGA complex (Fig. 6; Dorlfler 
and Busslinger, 1996; Eberhard and Busslinger, 1999; Emelyanov et al., 2002; Barlev et al., 2003). 
However, PAX5 can be converted into a transcriptional repressor by the Octapeptide (OP) domain 
and the Inhibitory domain (ID) (Fig. 6; Cobaleda et al., 2007). In fact, the OP domain interact with 
corepressors of the Groucho protein family, which are component of a histone deacetylase complex 
(HDAC), whereas the ID negatively regulates the adjacent TAD (Fig. 6; Dorlfler and Busslinger, 
1996; Eberhard et al., 2000). All the functional domain of human PAX5 are highly conserved in 
zebrafish (Pfeffer et al., 1998). 
 
Figure 6: Functional domains and interacting protein of Pax5. The consensus recognition sequence of 
Pax5 is shown. Dashed gray arrows indicate a likely but not yet proven interaction between the Pax5 
transactivation domain and the CREB-binding protein (CBP) or SAGA complex. Grg1–4 refers to the four 
full-length members of the mammalian Groucho protein family. Basal transcription machinery (BTM); histone 
acetyltransferase (HAT); partial homeodomain (HD); histone deacetylase (HDAC); inhibitory domain (ID); 
octapeptide domain (OP); transactivation domain (TAD); TATA-binding protein (TBP) (Cobaleda et al., 
2007). 
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2.3.2. PAX5 role in embryonic development 
During mouse embryo development Pax5 is transiently expressed in the mesencephalon at embryonic 
day (E) 11,5 and in the neural tube at E 12,5; Starting from E 13,5 Pax5 expression shifts to fetal 
liver, one of the sites of hematopoiesis in murine fetus, where it correlates with the onset of B 
lymphopoiesis (Adams et al., 1992). In adult mouse Pax5 is expressed in the testis and in several 
lymphoid tissues such as blood, spleen and lymph nodes (Adams et al., 1992). Accordingly, Pax5 is 
expressed in several cell lines representing the various B cell differentiation stages from pro-B to the 
mature B cell stages, however, Pax5 is not expressed in plasma cells, the terminal stage of B cell 
differentiation, and all other hematopoietic cell lines analyzed (Barberis et al., 1990; Adams et al., 
1992). Pax5 is the only Pax family member expressed in hematopoietic system and its important role 
in development has been shown by the generation of a Pax5 knockout mouse model. The Pax5 mutant 
mice usually die within three weeks after birth because of severe developmental defects of the central 
nervous system; moreover, B cell development in the bone marrow is arrested at an early precursor 
stage, the pro-B (or pre-BI) stage (Urbanek et al., 1994; Nutt et al., 1997). 
During zebrafish embryonic development pax5 is expressed in the brain, as in mouse and in Xenopus 
laevis (Adams et al., 1992; Short et al., 2012), specifically in the midbrain-hindbrain boundary from 
the 5 somite stage onwards (Fig. 7; Pfeffer et al., 1998). Later, pax5 expression is observed in the 
anterior part of the otic vesicle from the 17 somite stage to 72 hpf (Fig. 7; Pfeffer et al., 1998). 
Interestingly, pax5 is expressed in the otic vesicle also in Xenopus laevis, whereas in mouse it is not, 
thus suggesting that Pax5 expression in the otic vesicle has not been conserved in Amniotes during 
evolution (Adams et al., 1992; Pfeffer et al., 1998; Short et al., 2012). 
To understand the role of pax5 during zebrafish embryonic development Kwak and colleagues 
performed knock-down experiments by the injection of different morpholinos (Kwak et al., 2006). 
Morpholinos are antisense oligonucleotides designed to specifically bind the target mRNA and block 
protein translation, when using translation blocking morpholinos, or alter pre-mRNA splicing when 
using splicing blocking morpholinos (Nasevicius and Ekker, 2000; Eisen and Smith, 2008). Embryos 
injected with pax5 morpholinos (morphants) did not present any obvious phenotypical and 
morphological defects (Kwak et al., 2006). However, the analysis of vestibular-dependent functions 
of balance, motor coordination and swim bladder inflation displayed that about 20% of morphant 
embryos showed severely impaired vestibular function, while acoustic function appeared normal, 
thus indicating that pax5 is implicated in the development of the utricular macula and it is essential 
for vestibular function (Kwak et al., 2006). 
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Figure 7: pax5 expression during somitogenesis in zebrafish embryos. pax5 is expressed in the midbrain-
hindbrain boundary (mhb) and in the hindbrain (h) at 5 somites. At 20 somites it is expressed in the mhb and 
in the otic vescicle (Modified from Pfeffer et al., 1998). 
 
 
2.3.3. PAX5 role B cell development 
Now it is known that Pax5 is essential for several aspects of B cell development including: the 
commitment of B cell progenitors, the maintaining of cell identity throughout B lymphopoiesis until 
mature B cell stage and the immunoglobulin rearrangement (Cobaleda et al., 2007). 
B cell lineage commitment from the CLP depends on the basic-helix-loop-helix protein E2A, the 
Early B cell Factor 1 (EBF1), and Pax5 that function in a complex transcriptional network. The 
essential role of Pax5 in commitment of B cell precursors has been elucidated with a pro-B (or pre-
B) cell line obtained from Pax5-/- mice. These cells are able to differentiate into functional 
macrophages, granulocytes, dendritic cells, osteoclasts and natural killer cells both in vitro, when 
cultured with lineage-appropriate cytokines, and in vivo, upon transplantation into recipient mice; 
however, Pax5-/- cells can differentiate into mature B cells only after restoration of Pax5 expression 
consequently to retroviral transfection (Fig. 8; Nutt et al., 1999; Schaniel et al., 2002). 
Pax5 is fundamental not only for the commitment of B cell precursors but it is also essential for the 
maintaining of lineage identity throughout the differentiation process until mature B cell stage. In 
fact, conditional Pax5 deletion in mature B cell causes the de-differentiation back to early 
uncommitted pro-B progenitor in vivo (Fig. 8; Cobaleda et al., 2007b). 
To ensure the commitment and the maintaining of B cell identity Pax5 fulfils a dual role activating 
the expression of B cell specific genes and repressing the inappropriate ones. Pax5 activate the 
expression of several genes which are essential for B cells such as: Ebf1, Cd19, Cd79a and Blnk (Fig. 
9; Cobaleda et al., 2007). Ebf1 encodes another transcription factor that is necessary for B cell 
precursor commitment and it is in turn able to activate Pax5 expression (Roessler et al., 2007); CD19 
protein is a co-receptor of the BCR (Kozmik et al., 1992); Cd79a encodes the BCR component Ig 
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(Nutt et al., 1998); Blnk (B cell linker) is a cytosolic protein involved in the signal transduction of 
the BCR (Schebesta et al., 2002). There are several genes involved in the development of other blood 
cell lineages which must be repressed to allow the differentiation of B cell lineage (Fig. 9). Some of 
those repressed by Pax5 are: Csf1r, Notch1 and Lck. Csf1r encodes the macrophage colony 
stimulating factor receptor (Nutt et al., 1999); Notch1 encodes a transmembrane receptor involved in 
T cell precursors specification (Souabni et al., 2002). Lck encodes a tyrosine kinase involved in T cell 
development (Cobaleda et al., 2007). 
 
 
 
Figure 8: B cell lineage commitment by Pax5. The uncommitted Pax5–/– pro-B cells are able to differentiate 
into several hematopoietic cell types either in vitro in the presence of the indicated cytokines or in vivo after 
transplantation into recipient mice. Conditional Pax5 deletion (ΔPax5) results in retrodifferentiation of B 
lymphocytes to an uncommitted progenitor cell stage (Cobaleda et al., 2007). 
 
 
The progress of B cell maturation, especially the transition from pro-B to pre-B stage, depends on the 
proper signaling of the pre-BCR. One crucial step for the formation of a functional pre-BCR is the 
productive recombination of the immunoglobulin heavy chain locus (Igh), that results in the cell 
surface expression of the Ig protein as a part of the pre-BCR (Busslinger et al., 2004). The Igh locus 
is composed of three discontinuous segments: variable (V), diversity (D) and joining (J); V(D)J 
recombination occurs sequentially with DH-JH rearrangements preceding VH-DJH recombination and 
it is controlled at several steps by various transcription factors (Busslinger et al., 2004). Pax5 is 
important not only for the activation of Cd79a and Blnk expression, as previously mentioned, but also 
for the functional recombination of the Igh locus. In Pax5-/- pro-B cells DH-JH rearrangement proceeds 
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correctly, however VH-DJH recombination are reduced 100-fold compared to wild-type pro-B cells. 
Hence, Pax5 is involved in regulating the spatial organization of the Igh locus and it exerts this 
function inducing the contraction of the locus thus promoting VH-DJH recombination by facilitating 
connection formation between distal VH and proximal DH gene segments (Nutt et al., 1997; Hesslein 
et al.,2003) 
 
 
Figure 9: The role of Pax5 in B cell development. Pax5 represses lineage inappropriate genes and 
simultaneously activate B cell specific genes (Busslinger, 2004). 
 
 
2.4. PAX5 in hematological malignancies 
 
PAX5 was initially associated with hematological malignancies as target of genetic alterations in 
lymphomas. The translocation t(9;14)(p13;q32) brings one allele of PAX5 under the control of strong 
enhancers or promoters from the IgH locus and it has been associated with diffuse large B cell 
lymphomas (DLBCL), which are germinal-center B cell-derived tumors, and non-Hodgkin’s 
lymphoma (Busslinger et al., 1996; Lida et al.,1996; Morrison et al., 1998). These observations 
suggest that if the PAX5-dependent gene expression program is altered, due to increased PAX5 
transcription in B cells or failed PAX5 repression at the onset of plasma cell differentiation, the 
consequence could be tumor formation (Cobaleda et al., 2007). 
Despite lymphomas, PAX5 aberrancies have been found in ALL. PAX5 is located on the short arm of 
chromosome 9 which is subject to alterations, more commonly wide spread deletions, in about 10% 
of childhood ALL (Harrison, 2001). Notably, PAX5 gene is the most frequent target of somatic 
alterations in BCP-ALL, being affected in about 30% of pediatric and 34% of adult cases (Mullighan 
et al., 2007; Familiades et al., 2009). PAX5 alterations include: deletions, point mutations, 
amplifications and translocations. 
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The most frequent PAX5 alteration is deletion, that occur in about 25% of cases, and is divided into 
three types: wide-range deletion involving PAX5 and even the whole short arm of chromosome 9; 
focal deletions involving a subset of PAX5 exons extending to its 3’ region, thus leading to a 
prematurely truncated protein; focal deletions involving only a subset of internal PAX5 exons 
determining different PAX5 isoforms lacking functional domains (Mullighan et al., 2007). PAX5 
deletions seem to be secondary events because they are frequently associated with other alterations 
such as ETV6/RUNX1, BCR/ABL1 or TCF3/PBX1, both in adult and pediatric cases (Mullighan et al., 
2007; Familiades et al., 2009). 
PAX5 point mutations characterize about 7% of both adult and childhood cases (Mullighan et al., 
2007; Familiades et al., 2009). Modelling studies using the PAX5 crystal structure suggested that each 
of the nine point mutations founded in the paired box DNA binding domain should impair DNA 
binding activity. Also the transactivation domain is affected by point mutations, that consist of 
frameshift, splice site, or missense mutations (Mullighan et al., 2007). Despite mutations associated 
to ALL are usually acquired in somatic cells, it has been reported the existence of a recurrent germline 
PAX5 mutation which is associated with susceptibility to BCP-ALL in two unrelated kindreds. This 
mutation causes the substitution Gly183Ser in the octapeptide domain, reducing the activity of mutant 
PAX5 (Shah et al., 2013). Overall, the majority of PAX5 point mutations identified so far affect 
functional domains and result in reduced expression of PAX5 mRNA and lost or altered DNA-binding 
or transcriptional regulatory activity (Mullighan et al., 2007). 
PAX5 amplifications are less common and include partial amplification of a subset of internal exons 
and complete amplification of the gene (Mullighan et al., 2007; Familiades et al., 2009). 
Translocations of PAX5 occur in 2-3% of pediatric BCP-ALL cases and cause the fusion of PAX5 
with several partners, thus resulting in aberrant fusion genes that preserves the correct reading frame 
(Mullighan et al., 2007). The first case of a translocation resulting in an aberrant fusion gene involving 
PAX5 was identified in 2001, when was reported the fusion of PAX5 with ETV6 (Cazzaniga et al., 
2001). Since this first report, more than 20 partner genes have been identified in several chromosomes 
(An et al., 2008). The fusion genes can be subdivided into different groups according to the function 
of the PAX5 partner protein, which can be structural protein such as ELN, kinases such as JAK2, 
carriers of molecules, co-activator proteins, proteins involved in transcription regulation, 
transcription factors such as ETV6 and FOXP1 or proteins of unknown function like C20orf112. 
Despite several fusion genes involving PAX5 have been identified, clues of their biological activity 
in leukemogenesis process have been reported only for few of them and the role of fusion genes in 
leukemia is totally unknown for the majority of the identified alterations (Fazio et al., 2011). 
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Commonly, PAX5 fusion proteins result in the fusion of the N-terminal paired box DNA binding 
domain of PAX5 with the C-terminal region of the partner protein, whose domains substitute PAX5 
regulatory domains. These feature suggests that PAX5 fusion proteins could bind to the promoter 
region of PAX5 target genes and act as aberrant transcription factors thus deregulating the 
physiological pathway of wild type PAX5. Accordingly, PAX5/ETV6, PAX5/FOXP1 and 
PAX5/C20orf112 fusion proteins compete with wild-type PAX5 for the PAX5 binding sequences in 
reporter gene assays using the murine CD19 promoter (Kawamata et al., 2008). The ability of these 
fusion proteins to bind to PAX5 consensus sequence has various consequences both at molecular and 
cellular level; in fact, PAX5 fusion proteins, in vitro, are able to repress the expression of several 
PAX5 target genes, such as CD19, CD79a and BLNK, resulting in reduced PAX5 activity and causing 
the block of B cell differentiation. Hence, PAX5 fusion proteins act in a dominant negative manner 
over endogenous PAX5 protein (Fazio et al., 2008; Kawamata et al., 2008). However, PAX5/ETV6 
does not exclusively act in a dominant negative manner, but its role is more complex (Fazio et al., 
2008; Fazio et al., 2013); PAX5/ETV6 activity in leukemia will be discussed later in a specific 
chapter. 
Despite the role of PAX5 translocations has not been elucidated, there is a common feature that 
characterize patients carrying either a mutation, a deletion or a fusion gene, which is the significant 
downregulation of PAX5 expression or reduced levels of PAX5 protein and corresponding activity 
(Mullighan et al., 2007; An et al., 2008). This evidences, in addition to the finding that some PAX5 
fusion proteins act in a dominant negative manner, suggest that PAX5 haploinsufficiency could be a 
mechanism of leukemogenesis. However, B cell development occur normally in heterozygous Pax5+/- 
mice and conditional inactivation of Pax5 does not cause leukemia development in mice, instead, the 
complete loss of PAX5 in B cells leads to an aggressive progenitor cell lymphoma (Cobaleda et al., 
2007b). Moreover, human individuals carrying the heterozygous inherited PAX5 mutation 547G>A 
are mostly phenotypically normal or ‘subnormal’ in B cell development and all family members with 
BCP-ALL have also the concomitant deletion of the wild-type PAX5 allele. PAX5 547G>A, encoding 
Gly183Ser, is the only inherited PAX5 mutation identified so far and results in modest attenuation of 
PAX5 activity indicating that this partial hypomorphic allele is tolerated as a germline allele and 
additional genetic events further reducing PAX5 activity are required to establish the leukemic clone 
(Shah et al., 2013; Auer et al., 2014). 
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2.5. ETV6 
 
2.5.1. ETV6 gene and encoded protein structure 
 
 
Figure 10: ETV6 functiona domains. Helix-Loop-Helix (HLH) domain; internal domain; E-Twenty-Six 
(ETS) domain (Modified from De Braekeleer et al., 2012). 
 
 
ETV6 (E-Twenty-Six Variant gene 6), also known as TEL (Translocation Ets Leukemia), belongs to 
the ETS (E-Twenty-Six) family of transcription factor; in human it is located on chromosome 12 and 
has 8 exons (De Braekeleer et al., 2012). Also in zebrafish etv6 has 8 exons and it has been suggested 
that etv6 may be located on chromosome 4 however, it is not mapped on a specific chromosome in 
the actual assembly of the genome (GRCz10/danRer10; Montpetit and Sinnet, 2001). ETV6 gene 
encodes a 452aa nuclear protein that is characterized by the C-terminal ETS domain which is 
responsible for the binding of DNA at a purine-rich GGAA/T core motif within the promoter of the 
target genes (Fig. 10; Poirel et al., 1997). The nuclear localization of ETV6 depends on the C-terminal 
region of the protein, starting from amino acidic residue 332, that includes the ETS domain and 
contains a putative bipartite nuclear localization signal motif (Park et al., 2006). ETV6 protein is 
characterized also by the Helix-Loop-Helix (HLH) domain, also known as Pointed or Sterile Alpha 
Motif domain, located at the N-terminus of the protein (Fig. 10; Donaldson et al., 1996; Bohlander, 
2005). The HLH domain is involved in ETV6 homodimerization and oligomerization with other ETS 
proteins like Fli1 and ETV7 (Fig. 10; Kwiatkowski et al., 1998; Potter et al., 2000). ETV6 acts mainly 
as a transcriptional repressor consequently to homodimerization and heterodimerization with several 
repressor cofactors that are recruited by the HLH domain or the central region, also called internal 
domain, of ETV6 protein (Fig. 10; Lopez et al., 1999; Chakrabarti and Nucifora, 1999). The internal 
domain of ETV6 interact with SMRT, mSin3A and N-CoR corepressors that in turn can form a 
repressor complex with HDACs (Chakrabarti and Nucifora, 1999; Guidez et al.,2000). Differently, 
L(3)MBT polycomb group protein interacts with the HLH domain of ETV6 enhancing its ability to 
repress the activation of ETV6-responsive promoters in a HDAC independent manner (Boccuni et 
al., 2003). However, HLH domain is also involved in the recruitment of cofactors that can reduce 
ETV6 ability to repress transcription; in fact, HLH domain can bind to the ubiquitin-conjugating 
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enzyme UBC9, which positively modulates ETV6 transcriptional activity restoring the activation of 
a promoter that is repressed by ETV6 alone (Chakrabarti et al.,1999). The activity of ETS family 
proteins is regulated by Ras/MAP kinases through phosphorylation (Wasylyk et al., 1998). ETV6 is 
phosphorylated at multiple sites by p38 MAP kinase in vivo (Poirel et al., 1997; Arai et al., 2002). 
Specifically, phosphorylation at serine 22 residue is constitutive whereas phosphorylation at serine 
257 is inducible and reduces ETV6 repressive activity (Arai et al., 2002). A comparative analysis 
performed on ETV6 genes from human to fish showed a high degree of conservation of the HLH and 
ETS domains with an identity of 81% and 95% respectively between human and fugu (Takifugu 
rubripes) while the overall amino acid sequence identity and similarity between the fugu and human 
ETV6 proteins is 58% and 72%, respectively (Montpetit and Sinnet, 2001). Moreover, the serine 22 
and 257 phosphorylable residues are conserved in zebrafish (Montpetit and Sinnet, 2001). 
 
2.5.2. ETV6 role in embryonic development 
Etv6 expression pattern has been analyzed by northern blot and in situ hybridization in mouse 
embryos and adult tissues (Wang et al., 1997; Wang et al., 1998). Etv6 mRNA expression starts from 
E 7,0 and it markedly increases at E 17. At E 8,5 and E 9,5 Etv6 is expressed throughout the embryo 
and the yolk sac whereas at E 12,5 Etv6 mRNA is observed in several tissues and organs including 
cranial nerve ganglia, dorsal root ganglia, ventral region of the caudal neural tube, lung, kidney and 
liver; then, its expression is higher in the fetal liver and the thymus when compared with other tissues 
at E 14,5. Etv6 transcript is present in several adult mouse tissues such as the brain, the heart, the 
kidney, the spleen and the liver as well as various cell lines representing several blood cell lineages 
(Fig. 11; Wang et al., 1997; Wang et al., 1998). It has been reported that during zebrafish embryonic 
development etv6 is expressed in endothelial cells at 24hpf (Roukens et al., 2010). 
 
Figure 11: Etv6 is expressed in thymus, liver and lung of mouse embryo. In situ hybridization of Etv6 
performed on E14.5 paraffin-embedded embryos. Thymus (Th); Liver (Lv); Heart (Ht); Lung (Ln) (Modified 
from Wang et al., 1998). 
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Figure 12: Yolk sac angiogenic defects in Etv6-/- embryos. E9,5 Etv6-/- embryos lack branching vitelline 
vessels (Modified from Wang et al., 1997). 
 
 
To characterize the role of Etv6 in mammal development a knockout murine line (Etv6-/-) has been 
generated (Wang et al., 1997). Etv6 knockout is embryonic lethal and Etv6-/- mice die between E 10,5 
and E 11,5 with apoptosis of mesenchymal and neural cells and defective yolk sac angiogenesis, an 
alteration already observed in previous developmental stages (Fig. 12. Wang et al., 1997). 
Accordingly, ETV6 knockdown by means of short hairpin RNA (shRNA) expression in human 
umbilical vein endothelial cells (HUVECs) showed that ETV6 is essential for the sprouting of 
endothelial cells, a key mechanism in the angiogenesis process (Roukens et al., 2010). The role of 
Etv6 in endothelial cell sprouting is conserved from mammals to fish (Roukens et al., 2010). In fact, 
Etv6 knockdown by morpholino microinjection in zebrafish embryos caused the alteration of 
intersomitic vessels formation in 70-80% of the embryos; the observed defects are: reduction in the 
number of vessels, aberrant vessel trajectories and the premature stalling of dorsal aorta sprouts (Fig. 
13; Roukens et al., 2010). 
 
 
 
Figure 13: etv6 (tel) knockdown caused the alteration of intersomitic vessels formation in zebrafish 
embryos. Dorsal aorta (DA); dorsal longitudinal anastomotic vessel (DLAV); intersomitic vessels 
(ISV) (Modified from Roukens et al., 2010). 
 
 State of the Art  
25 
 
2.5.3. ETV6 role in hematopoiesis 
Consistent with its expression in murine blood cell lines, Etv6 is involved also in hematopoiesis 
(Wang et al., 1997; Wang et al., 1998). The generation of mouse chimeras with Etv6-/- embryonic 
stem cells (ESCs) showed that mutant ESCs do not contribute to bone marrow myelopoiesis and 
erythropoiesis in chimeras (Wang et al., 1998). Moreover, the conditional deletion of Etv6 using the 
Cre-Lox system caused the decrease of HSCs in the bone marrow, the site of definitive hematopoiesis 
in adult mice, while already committed hematopoietic cells derived from this HSCs are unaffected 
and transiently sustain blood formation (Hock et al., 2004). However, Hematopoiesis in yolk sac and 
fetal liver, the sites of hematopoiesis in murine fetus, occurs properly in Etv6 null mice suggesting 
that in mammals Etv6 is required for establishing hematopoiesis within the bone marrow but is 
dispensable for primitive and definitive embryonic hematopoiesis that occur in yolk sac and fetal liver 
(Wang et al., 1997; Wang et al., 1998; Hock et al., 2004). The role of Etv6 in hematopoiesis is not 
limited to the correct establishment of HSCs in the bone marrow but it is involved also in 
erythropoiesis (Waga et al., 2003; Takahashi et al., 2005; Eguchi-Ishimae et al., 2009). In fact, in 
vitro experiments showed that Etv6 expression in mouse erythroleukemia cells enhanced erythroid 
differentiation (Waga et al., 2003). Moreover, ETV6 overexpression in human leukemia cell line UT-
7/GM, that differentiates into erythroid cells if treated with erythropoietin or megakaryocytic lineages 
if exposed to thrombopoietin, inhibited megakaryocytic maturation and stimulated erythroid 
differentiation through the stimulation of hemoglobin synthesis and upregulation of erythroid 
differentiation specific genes (Takahashi et al., 2005). The role of Etv6 in erythropoiesis has been 
confirmed also in vivo by the generation of a transgenic mice line expressing human ETV6 under the 
control of Gata1 promoter (Eguchi-Ishimae et al., 2009). Hemoglobin concentration and red blood 
cell count was higher in peripheral blood of transgenic nice when compared with wild type mice 
while erythrocytes precursors isolated from bone marrow of transgenic mice are characterized by the 
upregulation of the erythroid specific genes Alas-e and -major globin and when these cells were 
cultured in vitro with EPO expanded more efficiently with respect to controls (Eguchi-Ishimae et al., 
2009). Overall, in vitro and in vivo experiments suggest that Etv6 stimulates erythroid proliferation 
and differentiation in mammals (Waga et al., 2003; Takahashi et al., 2005; Eguchi-Ishimae et al., 
2009). 
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2.6. ETV6 in hematological malignancies 
 
Somatic ETV6 mutations, including point mutations, insertions and deletions, have been found in 
myelodysplastic syndromes, acute myeloid leukemia, BCP-ALL and T cell ALL. The majority of 
these mutations result in truncated proteins lacking one or more ETV6 functional domains and are 
unable to repress transcription acting in a dominant negative manner (Barjesteh et al., 2005; Silva et 
al., 2008; Van Vlierberghe et al., 2011; Roberts et al., 2014). Recently, several germline ETV6 
mutations have been identified and affected families displayed mild to moderate thrombocytopenia, 
some of them red cell macrocytosis, and predisposition for skin cancer, myelodysplastic syndrome, 
chronic myelomonocytic leukemia, colon cancer, and, most commonly, BCP-ALL. Five mutations 
have been identified in the ETS domain and one in the central domain of ETV6. Each of these 
mutations abrogates ETV6 nuclear localization, causing the loss of transcriptional repression activity 
exerted by ETV6. Importantly, addition of wild type ETV6 was unable to restore transcriptional 
repression, suggesting that ETV6 mutants acts in a dominant negative manner (Noetzli et al., 2015; 
Topka et al., 2015; Zhang et al., 2015). 
The short arm of chromosome 12 is frequently involved in chromosomal rearrangements in leukemia 
and myelodysplastic syndromes. These rearrangements include unbalanced translocations and 
deletions, causing the loss of genetic materials, as well as balanced translocations (Bohlander, 2005). 
More than half of the balanced translocations have breakpoints located in the band 12p13 (Kobayashi 
et al., 1994). In 1994, Golub and colleagues identified a fusion of the Platelet Derived Growth Factor 
Receptor Beta gene (PDGFRB) located at band 5q31 to a previously unknown gene from 
chromosome 12 band p13, t(5;12)(q31:p13), which they called TEL (Translocation Ets Leukemia) 
and was later renamed to ETV6, in a patient with chronic myelomonocytic leukemia (Golub et al., 
1994). Since this first report, more than 40 chromosomal alterations causing ETV6 translocations, 
deletions and inversions have been identified; among these aberrancies 28 translocations have also 
been characterized at the molecular level and allowed the identification of 30 ETV6 partner genes 
(Fig. 14; Bohlander, 2005; De Braekeleer et al., 2012). ETV6 fusion genes can be subdivided into 
two groups according to the type of genes involved in the fusion: tyrosine kinases (PDGFRB, NTRK3, 
ABL1, JAK2) and transcription factors (RUNX1, CDX2, PAX5) (Fig. 14). 
ETV6 fusions involving tyrosine kinases are correlated with a wide spectrum of hematological 
malignancies which include chronic myelomonocytic leukemia, acute myeloid leukemia, BCP-ALL, 
T-cell ALL, chronic myeloproliferative neoplasm, myelodysplastic syndromes, T cell lymphoma and 
even with solid cancers (Golub et al., 1994; Golub et al., 1996; Lacronique et al., 1997; Peeters et al., 
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1997; Knezevich et al., 1998; Eguchi et al., 1999; Euhus et al., 2002; Kralik et al., 2011; De 
Braekeleer et al., 2011; De Braekeleer et al., 2012). 
Usually, ETV6/tyrosine kinases fusion proteins are characterized by the C-terminal region of ETV6 
containing the HLH dimerization domain and the N-terminal region of tyrosine kinases containing at 
least the kinase domain. The mechanism of leukemogenesis of these aberrant proteins depends on the 
HLH domain of ETV6, that causes the homodimerization of the fusion protein leading to the 
constitutive activation of the tyrosine kinase domain (Carroll et al., 1996; Golub et al.,1996; 
Lacronique et al.,1997). The ETV6/PDGFRB, ETV6/ABL1 and ETV6/JAK2 fusions have the 
potential to induce leukemic transformation in vivo, in fact, in a murine bone marrow transplant model 
they caused myeloproliferative syndrome (ABL and PDGFRB), fatal myeloid and 
lymphoproliferative diseases (JAK2) (Schwaller et al., 1998; Tomasson et al., 2000; Million et al., 
2002). The mechanism underlying leukemic transformation induced by ETV6 fusions with tyrosine 
kinases has been explained, at least in part, through the identification of the targets of aberrant kinases. 
In fact, ETV6/PDGFRB, ETV6/ABL1 and ETV6/JAK2 are able to phosphorylate and activate STAT 
proteins (Wilbanks et al., 2000; Spiekermann et al., 2002), which are essential for the production of 
mature hematopoietic cells via effects on cellular proliferation, survival and lineage-specific 
differentiation (Dorritie et al., 2014). 
 
 
Figure 14: Fusion gene network of ETV6. Transcriptional upregulation is indicated by a red arrow. A 
question marks denotes that this upregulation or the relevance of the upregulation has not been proven 
(Bohlander 2005). 
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ETV6 fusions with other transcription factors have been associated mainly with BCP-ALL, 
myelodysplastic syndromes, acute myeloid leukemia, chronic myeloid leukemia and 
myeloproliferative disorders (Bohlander, 2005; De Braekeleer et al., 2012). 
The translocations that causes the fusion o ETV6 with another transcription factor can alter the activity 
of one or both the partners in three ways: the ETV6 gene provide the promotor but any functional 
domain (ETV6/CDX2), the ETV6 gene provides the HLH domain to a partner gene in which the 
functional domains are retained (ETV6/RUNX1), ETV6 provides the HLH and ETS domains to a 
partner gene that is structurally modified by the fusion (PAX5/ETV6) (De Braekeleer et al., 2012). 
ETV6 does not contribute with functional domains in ETV6/CDX2 aberrant gene and it is likely that 
its promoter drives the transcription of CDX2 (Chase et al., 1999; Rawat et al., 2004). 
ETV6/RUNX1 is caused by the translocation t(12;21)(p13;q22) and is the most common 
rearrangement in pediatric BCP-ALL, accounting for about 22% of the cases. The fusion protein 
retains the HLH domain and the central repression domain of ETV6 as well as the DNA binding 
domain and the transcription activation domain of RUNX1 (Shurtleff et al., 1995; Mullighan, 2012). 
The ETV6/RUNX1 fusion protein retains the ability to bind the RUNX1 target sequences, but 
represses the expression of genes activated by RUNX1 (Hiebert et al., 1996; Guidez et al., 2000). 
Expression of ETV6/RUNX1 promotes self-renewal in B cell progenitors but alone does not induce 
leukemia (Andreasson et al., 2001; Morrow et al., 2004). In fact, the expression of ETV6/RUNX1 
under the control of the immunoglobulin heavy chain promoter did not cause leukemia in a transgenic 
mouse model suggesting that secondary genetic events are required to induce leukemia (Andreasson 
et al., 2001). This hypothesis is supported by the identification of additional recurring genetic 
alterations in ETV6/RUNX1 ALL, including deletions of PAX5, EBF1 and deletion of the second copy 
of ETV6 (Mullighan et al., 2007; Mullighan, 2012). 
 
 
2.7. PAX5/ETV6 
 
PAX5/ETV6 fusion gene has been described in 2001 in a patient with ALL. This aberrant gene results 
from the translocation t(9;12)(q11;p13) with the breakpoints located in intron 4 of PAX5 and intron 
2 of ETV6. This translocation did not cause the alteration of the reading frame, thus, the fusion gene 
encodes an aberrant protein that retains the paired box DNA binding domain of PAX5 and all ETV6 
functional domains, which are the HLH, the central and the ETS domains (Fig. 15; Cazzaniga et al., 
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2001). The translocation resulting in PAX5/ETV6 is the most common among PAX5 translocations 
(Mullighan et al., 2007; An et al., 2008; Kawamata et al.,2008). 
 
 
Figure 15: Schematic representation of PAX5, ETV6 and the resulting PAX5/ETV6 fusion protein. 
partial homeodomain (HD); inhibitory domain (ID); octapeptide domain (OPD); paired box domain (PD); 
transactivation domain (TAD); Helix-Loop-Helix (HLH) domain; internal domain; E-Twenty-Six (ETS) 
domain. 
 
 
It has been suggested that PAX5/ETV6 exerts a dominant negative activity on endogenous PAX5 
because it is able to interact with the PAX5-consensus sequence contained in the CD19 promoter, 
competing with wild type protein (Kawamata et al., 2008; Kawamata et al., 2012). Accordingly, the 
transfection of PAX5/ETV6 in murine pre-BI cell precursors derived from fetal liver caused the 
downregulation of several genes whose expression is activated by PAX5 such as CD19, BLNK and 
CD79a (Fazio et al.,2008). The conversion of PAX5 in a repressor seems to be mediated by the 
functional domains of ETV6, in fact, PAX5/ETV6 co-immunoprecipitates with the ETV6 co-
repressor mSin3a. However, PAX5/ETV6 activity is not strictly limited to a dominant negative effect, 
because gene expression profiling analysis showed that PAX5/ETV6 is able to down-regulate the 
expression of some PAX5-activated-genes, such as Cd79a and Blnk, as well as to up-regulate some 
PAX5-repressed-genes, such as Lck (Fazio et al., 2013). Thus, it has been proposed that PAX5/ETV6 
act in an “opposite dominant” manner instead of a canonical dominant negative effect. Interestingly, 
PAX5/ETV6 expression caused the reduction of endogenous Pax5 both at protein and at mRNA 
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levels, suggesting that PAX5/ETV6 activity, together with the loss of one allele of wild type PAX5 
that occur in translocated patients, could determines a PAX5 haploinsufficiency situation (Fazio et 
al., 2013). 
PAX5/ETV6 has been transfected in murine pre-BI cell precursors derived from fetal liver to study in 
vitro its role in the pathogenesis of leukemia. FACS analysis showed that cells transfected with 
PAX5/ETV6 downregulated B220 and CD19 proteins, which are B cell precursors specific antigens. 
Moreover, after the stimulation of B cell differentiation, control cells started to express  heavy chain 
whereas PAX5/ETV6 expressing cells did not, thereby highlighting the impairment of pre-BCR 
assembly and consequently the block of B cell differentiation (Fazio et al., 2008). 
PAX5/ETV6 confers also novel features to the expressing cells, such as an increased migration ability 
and survival advantages. In fact, PAX5/ETV6 enhanced cell migration ability toward CXCL12 
chemokine. Accordingly, it has been observed the upregulation of CXCR4, encoding a chemokine 
receptor involved in hematological malignancies (Burger and Burkle, 2007), in PAX5/ETV6 
expressing cells. Interleukin 7 is necessary for in vitro pre-BI cell survival and, although PAX5/ETV6 
does not confer IL-7 independence to pre-BI cells for prolonged periods, it gives a survival advantage 
under IL-7 starvation conditions. Moreover, pre-BI cells expressing PAX5/ETV6 grew in the presence 
of TGF1, a cytokine with antiproliferative and proapoptotic effects, showed increased proliferation 
and survival compared with control. 
The acquisition of these survival advantages in PAX5/ETV6 expressing cells is due, at least in part, 
to the activation of the Lck-STAT5 pathway (Fig. 16; Cazzaniga et al., 2015). In fact, PAX5/ETV6 
expression in murine cells caused the overexpression of Lck mRNA and the activation of Lck protein 
through the de-phosphorylation of the Lck inhibitory domain Y505. In turn, Lck causes the 
phosphorylation of STAT5 at the activator residue Y694 and consequently STAT5 activation leading 
to the overexpression of STAT5 effectors cMyc and Ccnd2. Accordingly, the treatment with the Lck 
activity inhibitor BIBF1120 caused a significant reduction of Stat5Y694 phosphorylation and reduced 
the replicative rate of PAX5/ETV6 expressing cells, thus abrogating their proliferative advantage. 
Interestingly, the increased LCK and STAT5 phosphorylation was observed also in cells from PAX5 
translocated patients and also in these cells the treatment with BIBF1120 caused the reduction of 
STAT5 phosphorylation (Fig. 16; Cazzaniga et al., 2015). 
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Figure 16: Mechanism of action of PAX5/ETV6 fusion protein in BCP-ALL. The pre-BCR is not 
expressed in PAX5/ETV6 expresing cells (A), causing the typical proliferation advantage and differentiation 
block of BCP-ALL (B). In particular, PAX5/ETV6 cause the up-regulation of LCK and its activation (C). LCK 
activation leads to STAT5 phosphorylation (D), thus sustaining proliferation and survival of blast cells via the 
transcription of STAT5 target genes (E). The administration of the LCK inhibitor BIBF1120 reverts this 
phenomenon, inhibiting STAT5 signaling (F) (Cazzaniga et al., 2015). 
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3. Aim of the Project 
 
The current knowledge about the role of PAX5/ETV6 fusion gene in the pathogenesis of leukemia 
derive only from in vitro studies and it is necessary to establish an in vivo model system which could 
be useful in future to gain new insights into the role of this aberrant gene in leukemia and to perform 
drug screenings. 
We are performing this project in collaboration with the group led by Dr. Giovanni Cazzaniga and 
Prof. Andrea Biondi which is currently studying the role of this aberrant gene in leukemogenesis in 
vitro, at the Tettamanti Foundation research center (San Gerardo hospital, University of Milano-
Bicocca, Monza). 
When we started this project there was no published information about the involvement of pax5 and 
etv6 in zebrafish hematopoiesis. Hence, the first issue to resolve was to verify the conservation of the 
roles of these genes in hematopoiesis during zebrafish development. To accomplish this task, we first 
analyzed the expression pattern of pax5 and etv6 by whole mount hybridization assays to verify if 
they are expressed in hematopoietic tissues during zebrafish development. Then, we performed loss 
of function experiments through the injection of morpholino anti-sense oligonucleotides for both pax5 
and etv6. In pax5 knockdown embryos, we analyzed the expression of several B cell markers to 
confirm that pax5 is involved in B cell lymphopoiesis also in zebrafish. Since it is known that etv6 is 
involved in erythrocytes differentiation, we tested the effect of etv6 loss of function on primitive 
erythropoiesis during zebrafish development and we tried to shed light on the potential molecular 
pathways which involve etv6 in this process. 
The final aim of this project is to verify if zebrafish could be a suitable model to study BCP-ALL 
related to PAX5/ETV6 fusion gene. To this end, we injected PAX5/ETV6 mRNA in zebrafish embryos 
and we tested if the expression of this aberrant gene is able to induce the same molecular alteration 
observed by in vitro experiments, such as the alteration of the expression of B cell markers and the 
activation of Lck-STAT5 pathway (Fazio et al.,2008; Fazio et al.,2013; Cazzaniga et al., 2015). 
It has been proposed that the loss of one wild type PAX5 allele and downregulation of PAX5 
expression or reduced levels of PAX5 protein in patients carrying either a mutation, a deletion or a 
fusion gene could be a mechanism of leukemogenesis (Mullighan et al., 2007; An et al., 2008). 
However, additional genetic events further reducing PAX5 activity are required to establish the 
leukemic clone (Cobaleda et al., 2007b; Mullighan et al., 2007; Shah et al., 2013; Auer et al., 2014). 
Since BCP-ALL patients carrying PAX5-ETV6 are also characterized by the mono-allelic losses of 
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PAX5 and ETV6, we decided to test if the contemporary pax5 and etv6 knock-down could cooperate 
to alter the expression of B cell markers. 
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4. Main Results 
 
4.1. pax5 is expressed in pancreas of zebrafish larvae and its knockdown 
alters the expression of B cell markers 
In order to verify that pax5 is expressed in organs involved in hematopoiesis during zebrafish 
development, we performed whole mount in situ hybridization (WISH) from 24 hpf to 5 dpf. In 
addition to the previously reported tissues (Pfeffer et al., 1998; Kwak et al., 2006; data not shown), 
we observed a weak staining of the pax5 probe in the gut and hybridization signals in liver and in 
pancreas, which has been proposed as a transient site of B cell development in zebrafish (Danilova 
and Steiner, 2002), from about 60 hpf to 5 dpf. Since it is not known if the role of pax5 in B cell 
development is conserved in zebrafish, we analyzed if pax5 knockdown causes the alteration of B 
cell markers expression at 5 dpf. The injection of a pax5 translation blocking morpholino (pax5-MO) 
caused the downregulation of igh and cd79a, as well as the upregulation of cd79b compared to 
control embryos, as showed by qRT-PCR assays. These findings suggest that the role of pax5 in B 
cell development could be, at least in part, conserved in zebrafish. 
 
4.2. etv6 is involved in primitive erythropoiesis in zebrafish 
We characterized the etv6 expression pattern by WISH assays and we found that etv6 is expressed in 
several hematopoietic tissues. Indeed, etv6 is expressed in the ALM and in the PLM at the 10 somite 
stage. Then, etv6 transcript is present in the ICM at the 20 somite and 24 hpf stages. At 36 hpf etv6 
is expressed in the caudal hematopoietic tissue (CHT), which a transient site of definitive 
hematopoiesis (Chen and Zon, 2009), and in the ventral wall of the dorsal aorta, that correspond to 
the Aorta-Gonad-Mesonephros (AGM). Besides hematopoietic tissues, etv6 is expressed also in the 
nervous system. 
To investigate the role of etv6 in hematopoiesis, we performed etv6 knockdown by the injection of a 
translation blocking morpholino that it has been already published and validated (Roukens et al., 
2010). However, we verified that etv6-MO causes the nonspecific activation of p53 (Robu et al., 
2007). Consequently, we decided to coinject etv6-MO and p53-MO in the subsequent experiments to 
suppress off-target effects and facilitate the study of specific loss of function phenotypes. 
Since etv6 is involved in erythropoiesis in mammals and we found that it is expressed in tissues 
related to primitive erythropoiesis (Waga et al., 2003; Takahashi et al., 2005; Eguchi-Ishimae et al., 
2009), we decided to verify if etv6 is involved in primitive erythropoiesis in zebrafish. Thus, we 
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analyzed the hemoglobin content of etv6 morphants by o-dianisidine staining and we found that 
primitive mature erythrocytes were reduced in etv6-MO/p53-MO coinjected embryos at 48 hpf. 
However, the production of primitive erythrocytes precursors is not impaired in etv6 morphants 
because we did not observe a decrease of circulating blood cells at 48 hpf and etv6 knockdown did 
not cause the alteration of the expression of primitive erythrocytes markers (hbbe1, hbbe3, gata1) at 
24hpf, when differentiation of primitive erythrocytes is about to start. So, we analyzed the expression 
of hbbe3 and gata1 at 48 hpf when these genes must be downregulated to allow primitive erythrocytes 
differentiation and we found that they are still up-regulated in etv6 morphant embryos suggesting that 
etv6 knock-down caused the alteration of primitive erythrocytes maturation. 
The increased activation of Notch pathway signaling and the consequent upregulation of the 
downstream target her6 can cause the alteration of primitive erythrocytes differentiation (Bresciani 
et al., 2010). Hence, we analyzed her6 expression by WISH assays and we found that it is upregulated 
and expanded in the PLM of etv6 morphants at 10 somites. Accordingly, the treatment with the Notch 
inhibitor DAPT partially rescued the alteration of primitive erythrocytes differentiation in etv6 
morphants at 48 hpf. Thus, the defective primitive erythrocytes maturation in etv6 morphants is, at 
least in part, caused by the increased activity of the Notch pathway. 
Recently, it has been reported that ETV6 mutations can alter the expression of KLF6 (Zhang et al., 
2015). The zebrafish klf6a gene, along with klf1, klf3 and klf17 is involved in the differentiation of 
primitive erythrocytes (Gardiner et al., 2007; Fu et al., 2009; Xue et al., 2015), we thus decided to 
test by q RT-PCR analysis if etv6 knockdown can cause the alteration of these genes. etv6 knockdown 
induced the statistically significant upregulation of klf3 and klf17 at 24 hpf as well as of klf1, klf3, 
klf6a and klf17 at 48 hpf. 
A recent report showed that etv6 knockdown caused the alteration of lymphoid precursors markers 
rag1 and ikaros (Rasighaemi et al., 2015). Hence, we tested if etv6 loss of function could induces the 
deregulation of B cell markers. Using qRT-PCR analysis we observed that etv6 knockdown caused 
the downregulation of igh, cd79a and blnk, whereas it induced the upregulation of cd79b. 
 
4.3. The injection of PAX5/ETV6 mRNA induced the activation of Lck-
Stat5 pathway but did not caused the alteration of B cell markers 
expression 
To verify if zebrafish could be a suitable model to study the role of PAX5/ETV6 fusion gene in BCP-
ALL, we transiently expressed the human PAX5/ETV6 gene in zebrafish embryos by the injection of 
 Main Results  
36 
 
two doses of its mRNA. However, the expression of cd79a and blnk was not statistically significant 
altered in embryos injected with PAX5/ETV6 mRNA at 5 dpf, while they are downregulated in B cell 
precursors in vitro (Fazio et al., 2008). 
PAX5/ETV6 caused the upregulation of Lck mRNA and enhanced Lck kinase activity in vitro 
(Cazzaniga et al., 2015). Thus, we analyzed the expression of lck by WISH assays at 5 dpf and we 
found that it is upregulated and expanded in the thymus of embryos injected with PAX5/ETV6 mRNA. 
Lck kinase activity is enhanced by phosphorylation of the tyrosine Y394 (Hui and Vale, 2014). To 
verify if PAX5/ETV6 causes the activation of Lck protein also in zebrafish, we performed western 
blot assays using an anti-LckY394 antibody and we found that the level of Lck phosphorylated protein 
is increased in embryos injected with PAX5/ETV6 mRNA in a dose dependent manner. 
The activation of Lck protein induced by PAX5/ETV6 in murine pre-BI cells is responsible for the 
phosphorylation of the STAT5 tyrosine residue 694, leading to the activation of the protein and the 
upregulation of the STAT5 effectors cMyc and Ccnd2 (Cazzaniga et al., 2015). Western blot assays 
performed at 5 dpf using an anti-STAT5Y694 showed that the injection of 250 pg/embryo of PAX5-
ETV6 mRNA strongly increased the level of STAT5Y694 phosphorylated protein in zebrafish embryos, 
whereas the injection of 200 pg/embryo of PAX5/ETV6 mRNA did not. 
Since the homologues of the murine STAT5 effectors cMyc and Ccnd2 are duplicated in zebrafish, 
we analyzed the expression of cmyca, cmycb and ccnd2a genes by qRT-PCR assays at 5dpf in 
embryos injected with PAX5/ETV6 mRNA. The expression of all the Stat5 effectors analyzed is 
statistically significant upregulated at both doses of PAX5/ETV6 mRNA showing a dose dependent 
effect. 
Thus, PAX5/ETV6 expression in zebrafish embryos is able to induce the phosphorylation and 
activation of Lck and Stat5, as well as the upregulation of the Stat5 effectors cmyca, cmycb and 
ccnd2a. 
 
4.4. pax5 and etv6 do not cooperate in the regulation of igh and cd79a 
expression 
Since etv6 knockdown caused the alteration of the expression of igh and cd79a which are impaired 
also in pax5 morphants, we decided to investigate if the contemporary pax5 and etv6 knock-down 
could cooperate to alter their expression. To this end we coinjected lower doses of both pax5 and etv6 
morpholinos. Using these doses, we observed the downregulation of igh in both pax5 and etv6 
single morphants, and cd79a in etv6 single morphants, however these variations are not statistically 
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significant when compared with control embryos. The coinjection of pax5 and etv6 morpholinos did 
not cause significant alteration of igh and cd79a expression if compared with single morphants or 
control embryos. Hence, these experiments seem to exclude a possible cooperation between pax5 and 
etv6 in the regulation of igh and cd79a expression. 
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5. Conclusions 
 
Zebrafish has proven to be a useful model to study physiological hematopoietic processes as well as 
pathological alterations involved in human hematological malignancies (Lieschke and Currie, 2007; 
Paik and Zon, 2010; Jing and Zon, 2011). However, despite many efforts have been made to deepen 
the knowledge of zebrafish hematopoiesis, very little is known about zebrafish B cell development. 
Our findings about pax5 expression in the pancreas of zebrafish embryos support the hypothesis 
proposed by Danilova and Steiner (2002) that the pancreas could be a transient site of B cell 
development in this teleost fish (Danilova and Steiner, 2002). 
In mammals, PAX5 is essential for B cell commitment and for the maintenance of B cell identity 
throughout B cell maturation (Cobaleda et al., 2007). Overall, our genetic evidences suggest that pax5 
role in B cell development could be, at least in part, conserved in zebrafish because pax5 loss of 
function determined the alteration of the expression of several components of the BCR such as cd79b, 
ighand cd79a. Since B cell emergence is a late event during zebrafish development, it will be 
necessary to establish pax5 mutant lines in order to study B cell phenotype in larval stages and adult 
fish to better characterize the role of pax5 in zebrafish B cell development. 
ETV6 accelerates erythroid differentiation of human and mouse leukemia cell lines and it stimulates 
hemoglobin synthesis in adult mice (Waga et al., 2003; Takahashi et al., 2005; Eguchi-Ishimae et al., 
2009). Accordingly, we found that etv6 is essential for primitive erythrocytes maturation. Morover, 
we tried to shed light into the mechanism through which etv6 regulates primitive erythrocytes 
maturation as a potential modulator of the notch signaling in primitive erythrocytes differentiation. 
Furthermore, etv6 could potentially influences several processes of erythrocytes differentiation via 
the modulation of klf genes expression. In fact, we show here that etv6 is involved, directly or 
indirectly, in the repression of several klf genes, which are essential for primitive erythrocytes 
maturation through the activation of multiple erythroid-specific genes (Palis, 2014). Thus, our 
findings suggest that etv6 role in hematopoiesis could be conserved from fish to mammals. However, 
we observed the alteration of primitive erythropoiesis whereas in mouse Etv6 is necessary only for 
adult hematopoiesis (Wang et al., 1997; Wang et al., 1998; Hock et al., 2004). 
The final aim of this study was to test if the expression of the human PAX5/ETV6 fusion gene in 
zebrafish embryos is able to induce the same molecular alterations observed in vitro (Fazio et al., 
2008; Fazio et al.,2013; Cazzaniga et al., 2015). PAX5/ETV6 expression confers survival advantages 
to pre-BI cells due to the activation of Lck protein, that in turn induces the phosphorylation and 
activation of STAT5 leading to the overexpression of STAT5 effectors cMyc and Ccnd2 (Cazzaniga 
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et al., 2015). Interestingly, we found that the amount of lck protein phosphorylated in the activator 
residue Y394 was increased in PAX5/ETV6 mRNA injected embryos in a dose dependent manner, 
thus indicating that PAX5/ETV6 can induce the activation of lck protein in zebrafish. Importantly, 
the zebrafish homologues of the murine STAT5 effectors cMyc and Ccnd2 are upregulated in a dose 
dependent manner in embryos injected with PAX5/ETV6 mRNA, suggesting that PAX5/ETV6 
expression activates the same pathways involved in the acquisition of the survival advantages showed 
by murine pre-BI cells. However, the level of Stat5 activated protein is increased only in embryos 
injected with the higher dose of the PAX5/ETV6 mRNA. It is conceivable that at the lower dose of 
PAX5/ETV6 mRNA the upregulation of cmyca, cmycb and ccnd2a could be induced by the activation 
of other unknown pathways. 
Overall, our results indicate that the molecular alterations caused by PAX5/ETV6 in vitro can be 
recapitulated in zebrafish, suggesting that zebrafish could be a good model system to study in vivo 
BCP-ALL associated to PAX5/ETV6. It will be useful to establish an inducible transgenic line to 
stably express the fusion gene also in later developmental stages and in adult fish to verify if longer 
expression of PAX5/ETV6 can induce the development of overt leukemia. To this end, we will 
establish a Gal4-UAS inducible transgenic line and we have already cloned the PAX5/ETV6 coding 
sequence in a vector used to generate transgenic fish through the tol2 transposon system (Kawakami, 
2007; Asakawa and Kawakami, 2008). 
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Abstract 
The PAX5 transcription factor is essential for B cell lineage commitment and differentiation. PAX5 
is target of alterations in about 30% of B cell precursors Acute Lymphoblastic Leukemia and the most 
recurrent among PAX5 translocations determines the generation of PAX5/ETV6 fusion gene. 
PAX5/ETV6 caused the alteration of B cell differentiation and conferred survival advantages in vitro 
due to the activation of the Lck-STAT5 pathway. The information currently available on PAX5/ETV6 
derive mainly from in vitro models, we thus tested whether zebrafish could be a good model to study 
this aberrant gene in vivo. To verify that the role of pax5 in B cell development is conserved in 
zebrafish, we analyzed its expression pattern and we found that it is expressed in pancreas, which has 
been proposed to be a transient embryonic site of B cell lymphopoiesis in zebrafish. Moreover, pax5 
knockdown caused the alteration of the expression of several B cell markers, suggesting that pax5 
role in B cell development could be conserved in zebrafish. Interestingly, etv6 knockdown caused the 
alteration of the expression of some B cell markers which are impaired also by pax5 loss of function, 
thus, we investigated if the contemporary pax5 and etv6 knock-down could cooperate to alter the 
expression of these genes. However, the coinjection of pax5 and etv6 morpholinos did not cause 
significant alteration of igh and cd79a, thus excluding a possible cooperation between pax5 and 
etv6 in the regulation of igh and cd79a expression. Finally, we transiently expressed PAX5/ETV6 
in zebrafish embryos and, despite it did not caused the deregulation of B cell markers expression, this 
aberrant gene is able to activate the same pathway which is altered in vitro, inducing the 
phosphorylation of Lck and Stat5 proteins as well as the upregulation of Stat5 effectors, suggesting 
that zebrafish could be a suitable model to study BCP-ALL related to PAX5/ETV6 fusion gene. 
 
  
 Manuscript  
54 
 
Introduction 
PAX5 (Paired box domain 5) belongs to the Paired Box family of transcription factors and the 
defining feature of PAX5 protein is the Paired Box DNA binding domain (PD; Czerny et al., 1993; 
Cobaleda et al., 2007). Transactivation activity of PAX5 is mediated by the partial Homeodomain 
(HD) and the Transactivation domain (TAD), however, PAX5 can be converted into a transcriptional 
repressor by the Octapeptide (OP) domain and the Inhibitory domain (ID; Dorlfler and Busslinger, 
1996; Eberhard and Busslinger, 1999; Eberhard et al., 2000; Emelyanov et al., 2002; Barlev et al., 
2003; Cobaleda et al., 2007). PAX5 is extensively studied in mammals for its essential role in B cell 
commitment and maturation. PAX5 fulfills its function mainly through the activation of B lineage-
specific genes and the repression of inappropriate ones (Cobaleda et al., 2007). Specifically, PAX5 
activates the expression of CD79a and BLNK, whereas repress LCK (Schebesta et al., 2002; Maier et 
al., 2003; Cobaleda, 2007). All the functional domain of human PAX5 are highly conserved in 
zebrafish (Pfeffer et al., 1998). During zebrafish embryonic development, pax5 is expressed in the 
midbrain-hindbrain boundary and in the anterior part of the otic vesicle where it is implicated in the 
development of the utricular macula and it is essential for vestibular function (Pfeffer et al., 1998; 
Kwak, 2006). However, there are no published data that confirm the involvement of pax5 in B cell 
development also in zebrafish. 
PAX5 is a frequent target of alterations in B cell precursors acute lymphoblastic leukemia (BCP-
ALL). In fact, about 30% of pediatric patients affected by BCP-ALL are characterized by mutations, 
deletions or translocations of the PAX5 gene (Mullighan et al., 2007). Translocations of PAX5 occur 
in 2-3% of pediatric BCP-ALL cases and cause the fusion of PAX5 with several partner genes 
encoding proteins with different functions, such as structural proteins, kinases, transcription factors 
and others (Mullighan et al., 2007; Nebral et al., 2009). The most recurrent PAX5 translocation is 
t(9;12), which leads to the generation of PAX5/ETV6 fusion gene and the mono-allelic losses of each 
wild type gene (Cazzaniga et al., 2001; Mullighan et al., 2007; An et al., 2008). The fusion gene 
encodes an aberrant protein that retains the paired box DNA binding domain of PAX5, while PAX5 
regulatory domains are substituted by ETV6 functional domains, which are the Helix-Loop-Helix, 
the central and the ETS domains (Cazzaniga et al., 2001). PAX5/ETV6 protein localizes in the 
nucleus and acts as an aberrant transcription factor altering the expression profile of murine B cell 
precursors in vitro (Cazzaniga et al., 2001; Fazio et al.,2013). PAX5/ETV6 is able to down-regulate 
the expression of some PAX5-activated-genes, such as Cd79a and Blnk, as well as to up-regulate 
some PAX5-repressed-genes, such as Lck, in a dominant manner versus the endogenous PAX5 (Fazio 
et al., 2008; Fazio et al.,2013). Among the genes whose expression is altered by PAX5/ETV6, there 
 Manuscript  
55 
 
are several ones involved in pre-BCR assembly and signaling, included Cd79a and Blnk. These 
alterations, together with the decreased expression of both cytoplasmic and transmembrane  heavy 
chain, lead to the impairment of pre-BCR assembly, that is essential for pre-BI cells survival, 
proliferation and differentiation (Fazio et al., 2008; Fazio et al.,2013). Accordingly, PAX5/ETV6 
caused the block of B cell differentiation and it also conferred novel features to the expressing cells, 
such as an increased migration ability and survival advantages (Fazio et al., 2008). The acquisition 
of these survival advantages in PAX5/ETV6 expressing cells is due to the activation of the Lck-
STAT5 pathway (Cazzaniga et al., 2015). PAX5/ETV6 expression in murine cells caused the 
activation of Lck protein. In turn, Lck induces the phosphorylation and activation of STAT5 leading 
to the overexpression of STAT5 effectors cMyc and Ccnd2. These molecular alterations are reverted 
upon the treatment with the Lck activity inhibitor BIBF1120, that also reduced the replicative rate of 
PAX5/ETV6 expressing cells, thus abrogating their proliferative advantage (Cazzaniga et al., 2015). 
Zebrafish has emerged as an excellent model organism because it allows to link genetic and molecular 
studies to morphological whole-organism analysis and it offers several advantages compared to other 
vertebrate model systems. The external fertilization and development, together with the optical clarity 
of the embryos allow in vivo and ex vivo easy visualization of embryonic development and 
manipulation of embryos. Zebrafish resulted to be particularly suitable for the study of hematopoiesis 
and hematopoietic disorders affecting humans, because the developmental processes and genetic 
programs of hematopoiesis, as well as the main blood cell types, are highly conserved (Lieschke and 
Currie, 2007; Paik and Zon, 2010; Jing and Zon, 2011). Despite zebrafish hematopoiesis has been 
extensively studied, very little is known about B-cell lymphopoiesis during zebrafish development, 
in fact, only Danilova and Steiner (2002) suggested that the pancreas could be an embryonic site of 
B cell development in zebrafish. This hypothesis is based on the expression of rag1 at 4 dpf (days 
post fertilization) and igh from 10 dpf in the pancreas. Subsequently, B cell development moves to 
the kidney at about 2 weeks post fertilization (wpf), when rag1 starts to be expressed in this organ, 
while ighexpression has been observed in the kidney at 19 dpf (Danilova and Steiner, 2002; Zapata 
et al., 2006). 
Zebrafish models of human leukemia caused by ETV6/RUNX1 and ETV6/JAK2 gene fusions have 
already been generated and they showed histological and molecular alterations referable to BCP-ALL 
and myeloid malignancies respectively. These findings suggest that zebrafish could be a useful model 
to reproduce and study the leukemic process in vivo (Onnebo et al., 2005; Sabaawy et al., 2006). 
Herein, we show that pax5 is expressed in tissues related to B cell lymphopoiesis during zebrafish 
development and that pax5 knockdown by means of morpholino microinjection caused the alteration 
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of the expression of several B cell markers, thus suggesting that pax5 is involved in in B cell 
development also in zebrafish. Moreover, we found that etv6 knockdown caused the alteration of 
some B cell markers which is impaired also by pax5 loss of function. This finding prompted us to 
investigate if the contemporary pax5 and etv6 knock-down could cooperate to alter the expression of 
B cell markers. Hence, we injected pax5 and etv6 morpholino together at lower doses, but the 
contemporary pax5 and etv6 knock-down did not cause a greater alteration of B cell markers 
expression compared to the single morphant embryos. Finally, we injected PAX5/ETV6 mRNA in 
zebrafish embryos and we verified that the expression of this aberrant gene is able to induce the same 
molecular alteration observed in vitro, suggesting that zebrafish could be a suitable model to study 
BCP-ALL related to PAX5/ETV6 fusion gene. 
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Materials and methods 
 
Zebrafish lines and maintenance 
Zebrafish (Danio rerio) embryos were raised and maintained under standard conditions and national 
guidelines (Italian decree 4th March 2014, n.26). All experimental procedures were approved by 
IACUC (Institutional Animal Care and Use Committee). Zebrafish AB wild-type strains were 
obtained from the Wilson lab, University College London, London, United Kingdom. For in vivo 
observations and imaging, embryos beyond 24 hpf were washed, dechorionated and anaesthetized 
with 0.016% tricaine (ethyl 3-aminobenzoate methanesulfonate salt; Sigma-Aldrich) before 
observations and picture acquisition. Embryos were staged according to morphological criteria 
(Kimmel et al., 1995). 
 
Whole mount in situ hybridization, embryo sectioning and imaging 
Whole mount in situ hybridizations were carried out as described (Thisse and Thisse, 2008). The 
riboprobes were synthesized using the Ambion® MAXIscript® SP6/T7 in Vitro Transcription Kit 
(Thermo Fisher Scientific) as described in the following papers: pax5 (Pfeffer et al., 1998), lck (Zhang 
et al., 2013). Images of stained embryos were taken on a Leica MZFLIII epifluorescence 
stereomicroscope equipped with a DFC 480 digital camera and LAS Leica imaging software (Leica, 
Wetzlar, Germany). Some of the hybridized embryos were then embedded in paraffin (Paraplast plus, 
Bio Optica) and sectioned (8m) on a microtome (Leitz 1516). The slides were mounted with Eukitt 
(Bio Optica) and all sections were observed using a Leica DM6000B microscope equipped with a 
DFC 480 digital camera and LAS Leica imaging software (Leica, Wetzlar, Germany). 
 
Real-time quantitative PCR assay and semi-quantitative RT-PCR 
Total RNA was isolated from embryos at different developmental stages using the SV Total RNA 
isolation System kit (Promega, Madison, Wisconsin, USA). After treatment with DNase I RNase-free 
(Roche, Basel, Switzerland), 1 g of RNA was reverse-transcribed using the ImProm-II™ Reverse 
Transcription System (Promega) according to manufacturer’s instructions. Real-time analysis was 
performed on Light Cycler 480II with Universal Probe Master system (Roche Diagnostics; F. 
Hoffmann-La Roche Ltd.). Primers and probes were selected according to the Software Probe Finder 
(Roche Diagnostics) and are reported in Supplementary Table S1. Data were expressed using the 
comparative ΔΔCt method, using rpl8 gene as reference and ctrl-MO or GFP mRNA injected 
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embryos as standardization control; both t test and SD values refer to triplicates of a single experiment 
and N=3 biological independent experiments were performed for each gene. 
To assess the non-specific activation of p53, semi-quantitative RT-PCR were performed with cDNA 
obtained from etv6 morphants at 24hpf. p53 and 113-p53 were subjected to 20 or 25 amplification 
cycles using primers reported in (Robu et al., 2007). 
 
Morpholino microinjection 
Antisense morpholinos were purchased from Gene Tools (LLC, Philomath, OR). Morpholinos were 
diluted in Danieau solution (Nasevicius and Ekker, 2000) and injected into 1-to-2 cell-stage embryos 
using Eppendorf FemtoJet Micromanipulator 5171. Rhodamine dextran (Molecular Probes, Life 
technology) was co-injected as dye tracer. etv6 knockdown was performed injecting 0,5pmol/embryo 
of a translation blocking MO (etv6-MO 5’-CATGTCTCGTTGAAATTCAGGAAGT‑3’) previously 
described (Roukens et al., 2010). pax5 knockdown was performed injecting 0,5pmol/embryo of a 
translation blocking MO (pax5-MO 5’-CGTGTTTGCAGTGGATTTCCATCGT-3’). A standard 
control oligo (ctrl-MO, 5’-CCTCTTACCTCAGTTACAATTTATA-3’, against human -globin 
gene) with no target in zebrafish embryos, was also used, to check for non-specific effects due to the 
injection procedure. Co-injection of etv6-MO with 0,75 pmol/embryo p53-MO was performed to 
abolish aspecific effects (Robu et al., 2007). 
 
Western blot analysis 
Embryo extracts were prepared as previously described (Bellipanni et al., 2000). Western blots were 
performed as previously described (Fazio et al.,2008). Primary antibody: Anti-beta-actin (AC-15, 
Sigma-Aldrich), anti-N-term PAX5 (AB4227, Chemicon), anti-LCK (Cell Signaling Technologies), 
anti-LCKY394 (Cell Signaling Technologies) anti-STAT5 (Cell Signaling Technologies), anti-
STAT5Y694 (Merck-Millipore). Densitometry analyses were performed using ImageJ software (U. S. 
National Institutes of Health, Bethesda, Maryland, USA). 
 
RNA microinjection 
PAX5/ETV6 coding sequence was subcloned from MIGR1 vector (Fazio et al., 2008) to pCS2+ 
plasmid and used as template for generating sense mRNA, in vitro synthesized using the mMessage 
mMachine kit (Ambion) according to the manufacturer’s instructions. 200 pg/embryo or 250 
pg/embryo of PAX5/ETV6 mRNA, diluted in RNase-free water, were injected into one-or two-cell-
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stage embryos with rhodamine dextran as dye tracer (Molecular Probes, Life technology). The GFP 
mRNA was injected as negative control. 
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Results 
 
pax5 is expressed in the pancreas of zebrafish larvae 
In order to verify that pax5 is expressed in organs involved in hematopoiesis during zebrafish 
development, we performed whole mount in situ hybridization (WISH) from 24 hpf (hours post 
fertilization) to 5 dpf. As it has been previously reported, pax5 is expressed in the midbrain-hindbrain 
boundary from the 5 somite stage onwards. Later, pax5 expression is observed in the anterior part of 
the otic vesicle from the 17 somite stage to 72 hpf (Pfeffer et al., 1998; Kwak et al., 2006; data not 
shown). Starting from about 60 hpf, we observed a weak staining of the pax5 probe in the gut and 
hybridization signals in the liver and in the pancreas (Fig. 1A-B), which has been proposed as a 
transient site of B cell development in zebrafish (Danilova and Steiner, 2002), in addition to the 
previously reported tissues. This expression pattern is maintained at least until 5 dpf (Fig. 1C-D). 
 
The B cell markers igh cd79a, cd79b, blnk, ebf1a and ebf1b are conserved in zebrafish and 
are highly expressed in larval developmental stages 
Previously to this work, the only B cell specific marker known to be conserved in zebrafish was 
igh(Danilova and Steiner, 2002). Hence, to gain new insights into B cell development and to 
identify the better stage to perform loss of function experiments we characterized the expression of 
several B cell markers by qRT-PCR. Specifically, besides igh(fig. 2B)the analysed markers are 
cd79a (fig. 2C), cd79b (fig. 2D), blnk (fig. 2A) and ebf1, which in zebrafish is duplicated in ebf1a 
(fig. 2E) and ebf1b (fig. 2F). The human CD79a and CD79b genes encode respectively Ig and 
Igthat, together with IgH protein, are components of the BCR, BLNK encodes an adaptor protein 
involved in B cell receptor signaling whereas EBF1 is a transcription factor necessary for B cell 
specification. To note, the expression of BLNK, CD79a and EBF1 is known to be directly activated 
by PAX5. qRT-PCR assays showed that the most of these genes are highly expressed in late larval 
stages, starting from about 72 hpf, during zebrafish development (fig. 2). Thus, as a compromise 
between the morpholino efficiency, which is most effective until about 72 hpf (Nasevicius and Ekker, 
2000), and the increase of B cell markers expression, we decided to perform functional experiments 
at 5 dpf. 
 
pax5 knockdown alters the expression of B cell markers 
Since it is not known if the role of pax5 in B cell development is conserved in zebrafish, we analyzed 
if pax5 knockdown causes the alteration of B cell markers expression.  
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Figure 1: pax5 is expressed in the pancreas of zebrafish larvae. WISH performed on zebrafish embryos at 
60 hpf and 5 dpf. (B, D) Transversal sections showing etv6 expression in the liver (l), in the pancreas (p) and 
in the intestine (in) at 60 hpf (B) and 5 dpf (D). (A, C) Lateral views; dorsal is up, anterior is left. (B, D) 
Transversal section of the trunk; dorsal is up. Abbreviations: cns, central nervous system; in, intestine; l, liver; 
n, notochord; p, pancreas; sb, swim bladder. 
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Figure 2: Analysis of B cell markers temporal expression. qRT-PCR assays of blnk (A), igh cd79a 
(C), cd79b (D), ebf1a (E)and ebf1b (F) performed at the indicated developmental stages from 64-128 cells to 
12 dpf. 
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pax5 loss of function experiments were performed by the injection of 0,5pmol/embryo of a 
morpholino designed to block pax5 translation (pax5-MO). qRT-PCR assays showed that pax5 
morpholino injection caused the downregulation of ighFC = 0,2 p < 0,01; Fig. 3C) and cd79a (FC 
= 0,3 p < 0,01; Fig: 3A), as well as the upregulation of cd79b (FC = 2,16 p < 0,05; Fig. 3B) compared 
to control embryos. However, there was no significant alteration of the expression of blnk (Fig. 3D), 
ebf1a and ebf1b (Fig. 3E and 3F) in pax5 morphants compared to control embryos. 
These findings suggest that the role of pax5 in B cell development could be, at least in part, conserved 
in zebrafish. 
 
etv6 knockdown causes the deregulation of the expression of B cell markers 
In mammals Etv6 is required for establishing hematopoiesis within the bone marrow but is 
dispensable for primitive and definitive embryonic hematopoiesis that occur in yolk sac and fetal liver 
(Wang et al., 1997; Wang et al., 1998; Hock et al., 2004). Recently, it has been reported that in 
zebrafish etv6 is involved in both primitive and definitive hematopoiesis. Moreover, etv6 knockdown 
caused the alteration of lymphoid precursors markers rag1 and ikaros (Rasighaemi et al., 2015). 
Hence, we tested if etv6 loss of function could induce the deregulation of B cell markers. To perform 
etv6 knockdown, we injected 0,5 pmol/embryo of a translation blocking morpholino that it has been 
already published and validated (Roukens et al., 2010). However, the injection of etv6 morpholino 
(etv6-MO) caused morphological alterations that were not previously described. Specifically, etv6 
knockdown caused apoptosis in brain tissue and curved tail at 24 hpf (Fig. S1A). It is known that 
some morpholino molecules could elicit p53 off-target activation causing nonspecific morphological 
defects similar to those observed in etv6 morphants (Robu et al., 2007). We verified that etv6-MO 
causes the upregulation of an N-terminal truncated p53 isoform that is diagnostic for the nonspecific 
p53 activation (Fig, S1B; Robu et al., 2007); moreover, etv6 morphants phenotype is rescued by p53-
MO coinjection (Fig. S1A). Consequently, we decided to coinject etv6-MO and p53-MO in the 
subsequent experiments to suppress off-target effects and facilitate the study of specific loss of 
function phenotypes. 
Using qRT-PCR analysis we observed the deregulation of several B cell markers in etv6 morphants. 
Indeed, in etv6-MO injected embryos ighFC = 0,28 p < 0,05; Fig. 4C), cd79a (FC = 0,31 p < 0,05; 
Fig. 4A) and blnk (FC = 0,62 p < 0,05; Fig. 4D) were downregulated, whereas cd79b (FC = 1,27 p < 
0,01; Fig. 4B) was slightly upregulated. However, the expression of ebf1a and ebf1b was comparable 
between control and etv6 morphant embryos (Fig. 4E and 4F). Thus, our results indicate that etv6 is 
involved in the regulation of the expression of igh, cd79a, blnk and cd79b.   
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Figure 3: pax5 knockdown causes the alteration of B cell markers expression. qRT-PCR analysis showing 
the downregulation of cd79a (A) and igh (C) as well as the upregulation of cd79b (B) in pax5-MO injected 
embryos at 5 dpf. The expression of blnk (D), ebf1a (E) and ebf1b (F) is comparable between control and pax5 
morphant embryos at 5 dpf. t test: * = p < 0,05; ** = p < 0,01. 
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Figure 4: etv6 loss of function determines the deregulation of B cell markers expression. qRT-PCR 
analysis showing the downregulation of cd79a (A), igh (C) and blnk (D) as well as the upregulation of cd79b 
(B) in etv6 morphants at 5 dpf. The expression of ebf1a (E) and ebf1b (F) is comparable between control and 
pax5 morphant embryos at 5 dpf. t test: * = p < 0,05; ** = p < 0,01. 
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pax5 and etv6 do not cooperate in the regulation of igh and cd79a expression 
It has been proposed that the loss of one wild type PAX5 allele and downregulation of PAX5 
expression or reduced levels of PAX5 protein in patients carrying either a mutation, a deletion or a 
fusion gene could be a mechanism of leukemogenesis (Mullighan et al., 2007; An et al., 2008). 
However, additional genetic events further reducing PAX5 activity or other genetic lesions are 
required to establish the leukemic clone (Cobaleda et al., 2007; Mullighan et al., 2007; Shah et al., 
2013; Auer et al., 2014). We observed that etv6 knockdown caused the alteration of the expression 
of some B cell markers which is impaired also in pax5 morphants and we wondered if the 
contemporary mono-allelic losses of PAX5 and ETV6 in BCP-ALL patients could influence the 
expression of these genes. We consequently decided to investigate if the contemporary pax5 and etv6 
knock-down could cooperate to alter the expression of igh and cd79a, which are both 
downregulated in pax5 and etv6 single morphants. The ideal setting to perform this experiment is to 
coinject subphenotypical doses of both morpholinos. Thus, we coinjected 0,2 pmol/embryo of both 
pax5 and etv6 morpholinos because the expression of igh in both pax5 and etv6 single morphants 
as well as cd79a in etv6 single morphants is still slightly downregulated but these variations are 
nevertheless not statistically significant when compared with control embryos. qRT-PCR assays 
showed that the coinjection of pax5 and etv6 morpholinos did not cause significant alteration of igh 
(Fig.S2B) and cd79a (Fig.S2A) expression if compared with single morphants or control embryos. 
Hence, these experiments seem to exclude a possible cooperation between pax5 and etv6 in the 
regulation of igh and cd79a expression. 
 
Transient expression of PAX5/ETV6 in zebrafish embryos 
Since we aimed to verify if zebrafish could be a suitable model to study the role of PAX5/ETV6 fusion 
gene in BCP-ALL, we transiently expressed PAX5/ETV6 in zebrafish embryos by the injection of its 
mRNA. To synthesize the mRNA, we previously sub-cloned the human PAX5/ETV6 coding sequence 
from the MIGR vector (Fazio et al., 2008) into the pCS2+ plasmid. The transient expression of 
PAX5/ETV6 was obtained by the injection of two doses of the mRNA, which was 200 pg/embryo and 
250 pg/embryo, while we injected the mRNA encoding the GFP protein as negative control. The 
expression of PAX5/ETV6 protein was confirmed by western blot analysis of PAX5/ETV6 mRNA 
injected embryo (Fig.S3A). We verified that PAX5/ETV6 is correctly transcribed and translated in 
vivo also by injection of pCS2+ vector containing the PAX5/ETV6 coding sequence (Fig.S3B), which 
induced a strong expression of the fusion protein due to its CMV promoter. Embryos injected with  
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either 200 or 250 pg/embryo of PAX5/ETV6 mRNA did not show morphological alterations until 5 
dpf, at this stage we observed a mild defect in yolk absorption (data not shown). 
 
PAX5/ETV6 did not cause the alteration of B cell markers in zebrafish embryos 
The expression of PAX5/ETV6 in murine pre-BI cells causes the downregulation of Cd79a and Blnk 
determining the block of pre-BCR assembly (Fazio et al., 2008). Thus, we analyzed their expression 
in PAX5/ETV6 mRNA injected embryos by qRT-PCR analysis at 5 dpf, however, we did not observe 
a statistically significant alteration of cd79a and blnk expression levels compared to control embryos 
(Fig.S4A, C). Moreover, also the expression of both igh and cd79b was comparable between control 
and PAX5/ETV6 mRNA injected embryos (Fig.S4B, D). 
 
The injection of PAX5/ETV6 mRNA induced the upregulation of lck and the activation of lck 
protein 
PAX5/ETV6 caused the upregulation of Lck mRNA and enhanced Lck kinase activity in vitro and in 
BCP-ALL patients with PAX5 fusion genes (Cazzaniga et al., 2015). Thus, we analyzed the 
expression of lck by WISH assays at 5 dpf in PAX5/ETV6 mRNA injected embryos. We found that 
lck expression in the thymus is upregulated and expanded in the 21% (n=19; Fig. 5B) and in the 38% 
(n=13; Fig. 5C) of embryos injected with 200 pg/embryo and 250 pg/embryo respectively of PAX5-
ETV6 mRNA compared to control embryos. 
Lck kinase activity is regulated through different phosphorylation events and the autophosphorylation 
of the tyrosine Y394 in the activation loop enhances the kinase activity (Hui and Vale, 2014). This 
tyrosine phosphorylation site is conserved in zebrafish, however it is located in the position 387 in 
the predicted lck protein (data not shown). To verify if PAX5/ETV6 causes the activation of Lck 
protein also in zebrafish, we performed western blot assays with protein extracts of PAX5/ETV6 
mRNA injected embryos using an anti-LckY394 antibody. The level of Lck phosphorylated protein, 
expressed as the ratio between LckY394 and Lck total protein, is increased of the 18% in embryos 
injected with 200 pg/embryo of PAX5-ETV6 mRNA compared to control embryos while the injection 
of 250 pg/embryo of PAX5/ETV6 mRNA determined the 54% increase of Lck phosphorylated protein 
(Fig. 5D). 
These results suggest that PAX5/ETV6 expression in zebrafish embryos causes the upregulation of 
lck expression and the activation of Lck protein in a dose dependent manner. 
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Figure 5: PAX6/ETV6 causes the upregulation of lck mRNA and the phosphorylation of Lck protein. 
(A-C) WISH assays showing the expression of lck in the thymus, indicated by the arrowhead, at 5 dpf. lck 
expression is increased and expanded in embryos injected with 250 pg/embryo (C) or 200 pg/embryo (B) of 
PAX5/ETV6 mRNA compared to controls injected with 250 pg/embryo of GFP mRNA. (A-C) Lateral views 
of the head, dorsal is up, anterior is left. (D) Western blot assays showing the expression of phosphorylated 
LckY394, total Lck and actin as internal control at 5 dpf. LckY394 phosphorylated protein is increased of 18% 
in embryos injected with 200 pg/embryo of PAX5/ETV6 mRNA and of 54% in embryos injected with 250 
pg/embryo of PAX5/ETV6 mRNA. 
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PAX5/ETV6 caused the activation of stat5 protein and the upregulation of stat5 effectors 
The activation of Lck protein induced by PAX5/ETV6 in murine pre-BI cells is responsible for the 
phosphorylation of the STAT5 tyrosine residue 694, leading to the activation of the protein and the 
upregulation of the STAT5 effectors cMyc and Ccnd2 (Cazzaniga et al., 2015). The mechanism of 
stat5 activation through the phosphorylation of Y694 is conserved in zebrafish (Lewis et al., 2006). 
Therefore, we performed western blot assays at 5 dpf using an anti-STAT5Y694 to test if the injection 
of PAX5-ETV6 mRNA is able to induce stat5 activation in zebrafish embryos. The injection of 200 
pg/embryo of PAX5-ETV6 mRNA did not cause an increase of STAT5Y694 phosphorylated protein. 
However, the level of STAT5Y694 was increased by 223% in embryos injected with 250 pg/embryo 
of PAX5-ETV6 mRNA compared to control embryos (Fig. 6A). 
The homologues of the murine STAT5 effectors cMyc and Ccnd2 are duplicated in zebrafish and we 
analyzed the expression of cmyca, cmycb and ccnd2a genes by qRT-PCR assays at 5dpf in embryos 
injected with 200 and 250 pg/embryo of PAX5-ETV6 mRNA. The expression of all the stat5 effectors 
analyzed was statistically significant upregulated at both doses of PAX5-ETV6 mRNA showing a 
dose dependent effect (Fig. 6B-D). 
Thus, PAX5/ETV6 expression in zebrafish embryos is able to induce the phosphorylation and 
activation of stat5, as well as the upregulation of the stat5 effectors cmyca, cmycb and ccnd2a. 
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Figure 6: PAX6/ETV6 induces the phosphorylation of Stat5 protein and the upregulation of ccnd2a, 
cmyca and cmycb. (A) Western blot assays showing the expression of phosphorylated Stat5Y694, total Stat5 
and actin as internal control. Stat5Y694 phosphorylated protein is increased of 323% in embryos injected with 
250 pg/embryo of PAX5/ETV6 mRNA. (B-D) qRT-PCR analysis showing the upregulation of ccnd2a (B), 
cmyca (C) and cmycb (D) in embryos injected with PAX5/ETV6 mRNA at 5dpf. The level of ccnd2a (B), 
cmyca (C) and cmycb (D) increase with the dose of PAX5/ETV6 mRNA injected. t test: * = p < 0,05; ** = p < 
0,01; *** = p < 0,001. 
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Discussion 
 
Zebrafish has proven to be a useful model to study physiological hematopoietic processes as well as 
pathological alterations involved in human hematological malignancies. The capability to reproduce 
human pathologies is due to the high conservation of the blood cell lineages and the molecular 
processes that regulate hematopoiesis (Lieschke and Currie, 2007; Paik and Zon, 2010; Jing and Zon, 
2011). Many efforts have been made to deepen the knowledge of zebrafish hematopoiesis, however 
very little is known about zebrafish B cell development. Thus, we searched the zebrafish homologues 
of several mammal B cell markers and we found that cd79a, cd79b, blnk and ebf1, which is duplicated 
in ebf1a and ebf1b, are conserved in zebrafish. The expression analysis of these genes, together with 
the previously characterized igh (Danilova and Steiner, 2002), showed that the majority of them are 
highly expressed during larval stages, which is consistent with previous findings that put the onset of 
B cell development at 4 dpf and the presence of clearly identifiable ighexpressing cells at about 10-
19 dpf (Danilova and Steiner, 2002; Zapata et al., 2006). Moreover, WISH analysis showed that pax5 
is expressed in the pancreas of zebrafish larvae, supporting the hypothesis proposed by Danilova and 
Steiner (2002) that the pancreas could be a transient site of B cell development in this teleost fish 
(Danilova and Steiner, 2002). 
In mammals PAX5 is essential for B cell commitment and for the maintenance of B cell identity 
throughout B cell maturation (Cobaleda et al., 2007). However, there are no published data suggesting 
that the role of pax5 in B cell is conserved in zebrafish. Thus, before testing if zebrafish could be a 
good model system to reproduce PAX5/ETV6 related leukemia, it has been necessary to verify if pax5 
is involved in zebrafish B cell development. pax5 knockdown by the injection of a translation 
blocking morpholino caused the alteration of several component of the B cell receptor, as assessed 
by qRT-PCR assays. Specifically, pax5 loss of function determined the downregulation of ighand 
cd79a, as well as the upregulation of cd79b. Interestingly, in mammals CD79a is a direct target of 
PAX5 (Nutt et al., 1998). However, the expression of blnk, ebf1a and ebf1b, which are directly 
activated by PAX5 in mammals (Schebesta et al., 2002), was not altered by pax5 knockdown. 
Therefore, it is possible that in zebrafish pax5 is not involved in the activation of blnk, ebf1a and 
ebf1b. However, it is also likely that the residual pax5 protein still present in pax5 knockdown 
embryos is sufficient to induce a normal expression of blnk, ebf1a and ebf1b. Overall, our genetic 
evidences suggest that pax5 role in B cell development could be, at least in part, conserved in 
zebrafish. Since B cell emergence is a late event during zebrafish development, it has been necessary 
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to establish pax5 mutant lines in order to study B cell phenotype in larval stages and adult fish to 
better characterize the role of pax5 in zebrafish B cell development. 
Patients carrying either a mutation, a deletion or a fusion gene involving PAX5 are characterized by 
the significant downregulation of PAX5 expression or reduced levels of PAX5 protein and 
corresponding activity (Mullighan et al., 2007; An et al., 2008). This evidences, in addition to the 
finding that some PAX5 fusion proteins act in a dominant negative manner, suggest that PAX5 
haploinsufficiency could be a mechanism of leukemogenesis. However, B cell development occur 
normally in heterozygous Pax5+/- mice and human individuals carrying the heterozygous inherited 
PAX5 mutation 547G>A are mostly phenotypically normal in B cell development and all family 
members who develop BCP-ALL have also the concomitant deletion of the wild-type PAX5 allele 
(Urbanek et al., 1994; Shah et al., 2013; Auer et al., 2014). Hence, additional genetic events further 
reducing PAX5 activity or other genetic lesions are required to establish the leukemic clone 
(Cobaleda et al., 2007; Mullighan et al., 2007; Shah et al., 2013; Auer et al., 2014). BCP-ALL 
patients carrying PAX5/ETV6 fusion are also characterized by mono-allelic losses of PAX5 and ETV6 
genes. Therefore, the concomitant deletion of one wild type of both these genes could have a role in 
the pathogenesis of leukemia. Since we found that etv6 knockdown caused the alteration of the 
expression of some B cell markers which are impaired also by pax5 loss of function, we investigated 
if the contemporary pax5 and etv6 knock-down could cooperate to alter the expression of these genes. 
However, the coinjection of lower doses of pax5 and etv6 morpholinos did not cause significant 
alteration of igh and cd79a, thus excluding a possible cooperation between pax5 and etv6 in the 
regulation of igh and cd79a expression. 
The final aim of this study was to test if the expression of the human PAX5/ETV6 fusion gene in 
zebrafish embryos is able to induce the same molecular alterations observed in vitro in murine pre-
BI cells (Fazio et al., 2008; Fazio et al.,2013; Cazzaniga et al., 2015). One of the alterations caused 
by PAX5/ETV6 in pre-BI cells is the block of pre-BCR assembly through the downregulation of the 
PAX target genes Cd79a and Blnk (Fazio et al., 2008). However, the expression of these genes, as 
well as igh and cd79b, is not deregulated by the expression of PAX5/ETV6 in zebrafish embryos. 
Now it is thought that leukemia is a multi-step process in which multiple genetic lesions cooperate to 
oncogenic transformation, in fact many of the known alterations alone are not sufficient to induce 
leukemia in experimental models (Greaves et al., 2003; Mullighan et al., 2007; Pui et al., 2008; Inaba 
et al., 2013). Thus, it is possible that in zebrafish the expression of PAX5/ETV6 fusion gene alone is 
not sufficient to cause the alteration of the analysed B cell markers in vivo or a longer experimental 
time is needed for leukemia development. 
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PAX5/ETV6 expression confers survival advantages to pre-BI cells due to the activation of Lck 
protein, that in turn induces the phosphorylation and activation of STAT5 leading to the 
overexpression of STAT5 effectors cMyc and Ccnd2 (Cazzaniga et al., 2015). We thus tested if the 
expression if the injection of PAX5/ETV6 mRNA is able to cause the same alterations in zebrafish 
embryo and we observed that lck expression is upregulated in a dose dependent manner. Moreover, 
the amount of Lck protein phosphorylated in the activator residue Y394 is increased in PAX5/ETV6 
mRNA injected embryos in a dose dependent manner, therefore indicating that PAX5/ETV6 can 
induce the activation of Lck protein in zebrafish. 
Importantly, the zebrafish homologues of the murine STAT5 effectors cMyc and Ccnd2 are 
upregulated in a dose dependent manner in embryos injected with PAX5/ETV6 mRNA, suggesting 
that PAX5/ETV6 expression activates the same pathways involved in the acquisition of the survival 
advantages showed by murine pre-BI cells. However, the level of Stat5 activated protein is increased 
only in embryos injected with the higher dose of the PAX5/ETV6 mRNA. It is conceivable that at the 
lower dose of PAX5/ETV6 mRNA the upregulation of cmyca, cmycb and ccnd2a could be induced 
by the activation of other not yet identified pathways. 
Overall, our results indicate that the molecular alterations caused by PAX5/ETV6 in vitro can be 
recapitulated in zebrafish, suggesting that zebrafish could be a good model system to study in vivo 
BCP-ALL associated to PAX5/ETV6. It will be useful to establish an inducible transgenic line to 
stably express the fusion gene also in later developmental stages and in adult fish to verify if longer 
expression of PAX5/ETV6 can induce the development of overt leukemia. Such studies of the 
leukemic process could be useful for the identification of new potential therapeutic targets. Moreover, 
zebrafish embryos are permeable to soluble molecules dissolved in the culture medium and are 
particularly suitable for large scale drug screenings (Lieschke and Currie, 2007; Paik and Zon, 2010; 
Jing and Zon, 2011). Thus, zebrafish model of PAX5/ETV6-related BCP-ALL could be used to 
perform drug screenings in vivo in order to identify novel therapeutic compounds.  
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Supplementary figure legends 
 
Figure S1: etv6-MO induces the non-specific activation of 113-p53. (A) The injection of 0,5 
pmol/embryo of etv6-MO causes apoptosis in brain tissue and curved tail at 24 hpf. These alterations 
are rescued by the co-injection of 0,75 pmol/embryo of p53-MO along with etv6-MO. (B) Semi-
quantitative RT-PCR performed at 24 hpf showing that etv6-MO injection induces the upregulation 
of 113-p53, encoding a truncated p53 isoform which is considered diagnostic for non-specific p53 
activation caused by some morpholino molecules (Robu et al., 2007). Also the semi-quantitative RT-
PCRs of p53 and actin are reported. actin amplification at 25 cycles is shown to compare the 
saturation level. 
 
Figure S2: pax5 and etv6 double knockdown does not cooperate to alter the expression of igh 
and cd79a. The coinjection of 0,2 pmol/embryo of etv6-MO with 0,2 pmol/embryo of pax5-MO did 
not induce the alteration of igh and cd79a expression at 5 dpf, as assessed by qRT-PCR assays. 
 
Figure S3: Expression of PAX5/ETV6 in zebrafish embryos. Western blot assays performed with 
an anti-human-PAX5 antibody (Chemicon) showing the expression of PAX5/ETV6 protein in 
zebrafish embryos injected with 200 pg of PAX5/ETV6 mRNA (A) and 100 pg of pCS2+ vector 
containing the PAX5/ETV6 coding sequence. The protein extracts were obtained from embryos at 30 
hpf (A) and 4 dpf (B). 
 
Figure S4: The expression of B cell markers is not altered in embryos injected with PAX5/ETV6 
mRNA. The expression of cd79a (A), cd79b (B), blnk (C) and igh (D) at 5 dpf is comparable 
between embryos injected with PAX5/ETV6 mRNA and GFP mRNA. 
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Supplementary figures 
 
Figure S1 
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Figure S2 
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Figure S4 
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Supplementary Table S1. List of primers and UPL probe number used. 
Gene name Primer sequence Probe number 
z_rpl8 fw tcaagggaatcgtgaaggac 82 
z_rpl8 rev gggtcacgaaacatcacctt 
z_blnk fw caaaatgaacaagcggctaat 47 
z_blnk rev gcggctctttcttcttcagtc 
z_ccnd2a fw atcagaccgcaagaactgct 24 
z_ccnd2a rev tgacagctgctaggttccac 
z_cd79a fw tgaataaactggacaggaagacag 69 
z_cd79a rev tgcagtcatccagattaagacc 
z_cd79b fw cctcttggttttgtgcattg 6 
z_cd79b rev tcagcctcttctttcttctcca 
z_cmyca fw ggtcctggacactccaccta 59 
z_cmyca rev tcctcctcctcatcctcttct 
z_cmycb fw agcagtagtgacagcgaatcc 35 
z_cmycb rev ccgtgaccacgtcaatttct 
z_ebf1a fw ggatgccacacaataatcagg 84 
z_ebf1a rev acgcgggacattgtagagag 
z_ebf1b fw tgctgccaattcaccctac 19 
z_ebf1b rev agtttgagggtaggctggtg 
z_igh fw gccccaaaaacagcttctc 22 
z_ igh rev gaacacagttgcacgcagat 
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etv6 is involved in primitive erythropoiesis in zebrafish 
 
Abstract 
ETV6 is a transcription factors that is frequently involved in chromosomal translocations in various 
hematological malignancies. It was shown that ETV6 is required specifically for hematopoiesis of all 
lineages within the bone marrow, which is the site of definitive hematopoiesis, but not in the yolk sac 
and fetal liver in mice, the sites of primitive hematopoiesis. Moreover, ETV6 accelerates erythroid 
differentiation of human and mouse leukemia cell lines and it stimulates hemoglobin synthesis in adult 
mice. To characterize the role of etv6 during zebrafish development we first analyzed its expression 
pattern and we found that it is expressed in several hematopoietic tissues. Indeed, etv6 is expressed in 
the Anterior and Posterior Lateral Mesoderm, in the Intermediate Cell Mass, in the Caudal Hematopoietic 
Tissue and in the Aorta-Gonad-Mesonephros region. Moreover, etv6 loss of function determined the 
reduction of primitive mature erythrocytes and we found that this alteration is due to the defective 
differentiation of primitive erythrocytes. Interestingly, the alteration of primitive erythrocytes 
differentiation induced by etv6 knockdown is, at least in part, due to the activation of Notch pathway. In 
fact, etv6 loss of function caused the upregulation of the Notch effector her6 and the treatment with the 
Notch pathway inhibitor DAPT partially rescued the alteration of primitive erythrocytes differentiation. 
Finally, etv6 is involved, directly or indirectly, in the repression of klf1, klf3, klf6a and klf17 genes, which 
are essential for primitive erythrocytes maturation. Thus, we show here that etv6 is a fundamental 
regulator of primitive erythrocytes differentiation through the regulation of klf genes expression and the 
modulation of the Notch pathway signalling. 
 
Introduction 
ETV6 (E-Twenty-Six Variant gene 6), also known as TEL (Translocation Ets Leukemia), belongs to the 
ETS (E-Twenty-Six) gene family and encodes a transcription factor that is characterized by the C-terminal 
ETS domain which is responsible for the binding of DNA (Poirel et al., 1997). ETV6 protein is 
characterized also by the N-terminal Helix-Loop-Helix (HLH) domain, also known as Pointed or Sterile 
Alpha Motif domain, which is involved in ETV6 homodimerization and oligomerization with other ETS 
proteins like Fli1 and ETV7 (Donaldson et al., 1996; Kwiatkowski et al., 1998; Potter et al., 2000; 
Bohlander, 2005). It has been suggested that ETV6 acts mainly as a transcriptional repressor 
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consequently to the recruitment of several repressor cofactors by the HLH domain or the central region 
of ETV6 protein (Lopez et al., 1999; Chakrabarti and Nucifora, 1999; Guidez et al.,2000; Boccuni et al., 
2003). 
During mouse development Etv6 is expressed in several tissues and organs, but its expression is higher 
in the fetal liver and the thymus. Moreover, Etv6 transcript is present in various cell lines representing 
several blood cell lineages. Consistent with its expression in murine blood cell lines, Etv6 is required for 
establishing hematopoiesis within the bone marrow but is dispensable for embryonic hematopoiesis that 
occur in yolk sac and fetal liver (Wang et al., 1997; Wang et al., 1998; Hock et al., 2004). The role of 
Etv6 is required also in erythropoiesis. In fact, ETV6 accelerates erythroid differentiation of human and 
mouse leukemia cell lines and it stimulates hemoglobin synthesis in adult mice (Waga et al., 2003; 
Takahashi et al., 2005; Eguchi-Ishimae et al., 2009). 
In zebrafish, primitive erythroid precursors originate from the posterior lateral plate mesoderm (PLM) 
around 5 somite stage. Around 18 somite stage, these precursors migrate to the intermediate cell mass 
(ICM). Within the ICM, erythroid progenitors differentiate in proerytrhroblasts that enter the circulation 
at 24-26 hpf (hours post fertilization; Detrich et al., 1995). These cells continue to mature in circulation 
and are the only circulating red cell population through 4dpf (Weinstein et al., 1996; Chen and Zon, 
2009). Erythrocytes differentiation consists in cytological changes in cell size and in nuclear shape that 
are accompanied by ‘maturational’ globin switching as erythrocytes differentiate (Ransom et al., 1996; 
Ganis et al., 2012). The members of the Kruppel-like transcription factor family are important 
transcriptional regulators of erythropoiesis, particularly of erythrocytes maturation, because are known 
to activate several erythroid-specific genes (Donze et al., 1995; Hodge et al., 2006; Pilon et al., 2006; 
Gardiner et al., 2007; Fu et al., 2009; Palis, 2014 Xue et al., 2015). 
Recently, it has been reported that etv6 is involved in both primitive and definitive hematopoiesis during 
zebrafish development (Rasighaemi et al., 2015). We confirm here that etv6 is expressed in tissues 
involved in both primitive and definitive hematopoiesis and that etv6 is essential for primitive 
erythrocytes maturation. Moreover, we tried to shed light into the mechanism through which etv6 
regulates primitive erythrocytes maturation. Interestingly, we found that etv6 is a potential modulator of 
the notch signaling in primitive erythrocytes. Furthermore, etv6 is involved, directly or indirectly, in the 
repression of klf1, klf3, klf6a and klf17 genes, which are essential for primitive erythrocytes maturation 
(Gardiner et al., 2007; Fu et al., 2009; Xue et al., 2015). 
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Results and discussion 
To characterize the etv6 expression pattern we performed whole mount in situ hybridization (WISH) and 
we found that it is expressed in several hematopoietic tissues. Indeed, etv6 is expressed in the anterior 
lateral mesoderm (ALM) and in the PLM at the 10 somite stage (Fig. 1A, B, D). Then, etv6 transcript is 
present in the ICM at the 20 somite and 24 hpf stages (Fig. 1E, H). The PLM is the region where the 
primitive erythroid precursors are generated, whereas in the ICM they start the differentiation process 
(Detrich et al., 1995). At 36 hpf etv6 is expressed in the caudal hematopoietic tissue (CHT; Fig. 1L), 
which is a transient site of definitive hematopoiesis (Chen and Zon, 2009), and in the ventral wall of the 
dorsal aorta (Fig. 1L-N), which corresponds to the Aorta-Gonad-Mesonephros (AGM) region. The 
definitive HSCs emerge from this region, they enter circulation through the axial vein and migrate first 
to the CHT and then to the organs that will be the sites of adult hematopoiesis, which are the thymus and 
the kidney marrow, the analogous of the bone marrow in mammals (Murayama et al., 2006; Jin et al., 
2007; Bertrand et al., 2008; Kissa et al., 2008; Bertrand et al., 2010; Kissa and Herbomel, 2010). Besides 
hematopoietic tissues etv6 is expressed also in the nervous system. In fact, etv6 transcript is present in 
the neural tube at 10 and 20 somite stages (Fig. 1C, E, G). At the latter stage, etv6 is expressed also in 
the cranial ganglia (Fig. 1F). Its expression in this region is maintained at 24 hpf (Fig. 1I), when etv6 
transcript is present in the brain, specifically in the mesencephalon, in the cerebellum and in the hindbrain 
(Fig. 1H). This expression pattern in brain is the same at 36 hpf (Fig. 1L). 
To characterize the role of etv6 in hematopoiesis, we performed etv6 knockdown by the injection of 0,5 
pmol/embryo of a translation blocking morpholino that it has been already published and validated 
(Roukens et al., 2010). The injection of etv6 morpholino (etv6-MO) caused morphological alterations 
that were not previously described. Specifically, etv6 knock-down caused apoptosis in brain tissue and 
curved tail at 24 hpf (Fig. S1A). It is known that some morpholino molecules could elicit p53 off-target 
activation causing nonspecific morphological defects similar to those observed in etv6 morphants (Robu 
et al., 2007). We verified that etv6-MO causes the activation of an N-terminal truncated p53 isoform that 
is diagnostic for the nonspecific p53 activation (Fig. S1B; Robu et al., 2007); moreover, etv6 morphants 
phenotype is rescued by p53-MO coinjection (Fig. S1A). Consequently, we decided to coinject etv6-MO 
along with p53-MO in the subsequent experiments to suppress off-target effects and facilitate the study 
of specific loss of function phenotypes. 
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Figure 1: etv6 is expressed in hematopoietic tissues during zebrafish development. WISH analysis showing 
etv6 expression pattern from 10 somite (s) stage to 36 hpf. (A-D) At 10 somites stage etv6 transcript is present in 
the anterior lateral mesoderm (alm), in the posterior lateral mesoderm (plm) and in the neural tube (nt). (E-G) At 
20 somites stage etv6 expression in the neural tube is maintained and was expressed also in the intermediate cell 
mass (icm) and in cranial ganglia (cg). (H, I) At 24 hpf etv6 mRNA is still present in the icm and in cg, while it is 
present also in the brain, specifically, in the hindbrain (h), in the cerebellum (c) and in the mesencephalon (m). (L-
N) At 36 hpf etv6 is expressed in the aorta-gonad-mesonephros region (agm) and in the caudal hematopoietic 
tissue (cht). (M) Detail of the trunk of the embryo depicted in (L). (N) Transversal section of an embryo at 36 hpf 
showing that etv6 hybridization signal is present in endothelial cells of the dorsal aorta (da) and of the posterior 
cardinal vein (pcv) as well as in the pronephros. (A, E, H, L, M) Lateral views; dorsal is up, anterior is left. (C, G, 
I) Dorsal views, anterior is left. (B, F) anterior views, posterior is right. (D) Posterior view, anterior is left. (N) 
Transversal section of the trunk; dorsal is up. Abbreviations: agm, aorta-gonad-mesonephros; alm, anterior lateral 
mesoderm; cht, caudal hematopoietic tissue; c, cerebellum; h, hindbrain; icm, intermediate cell mass; m, 
mesencephalon; plm, posterior lateral mesoderm; nt, neural tube. 
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Since etv6 is involved in erythropoiesis in mammals and we found that it is expressed in tissues related 
to primitive erythropoiesis (Waga et al., 2003; Takahashi et al., 2005; Eguchi-Ishimae et al., 2009), we 
decided to investigate if etv6 is involved in primitive erythropoiesis in zebrafish. Thus, we analyzed the 
hemoglobin content of etv6 morphants by whole embryo o-dianisidine staining in order to assess the 
presence of primitive differentiated erythrocytes. Primitive mature erythrocytes appeared reduced in the 
90% (n=41) of etv6-atg-MO/p53-MO coinjected embryos at 48 hpf compared to control embryos (Fig. 
2A), thus indicating an alteration of primitive erythropoiesis. However, we did not observe circulatory 
defects nor a decrease of circulating blood cells at 48 hpf in morphant embryos (data not shown), 
suggesting that etv6 loss of function did not cause the reduction of primitive erythrocyte precursors. To 
further verify that the production of primitive erythrocyte precursors is not impaired in etv6 morphants, 
we analyzed the expression of some primitive erythrocytes markers at 24hpf, at the onset of primitive 
erythrocytes differentiation (Detrich et al., 1995). Specifically, we analyzed the expression of: gata1, the 
master regulator of erythropoiesis (Fujiwara et al., 1996; Galloway et al., 2005; Rhodes et al., 2005), 
alas2, which encodes an enzyme involved in hemoglobin synthesis (Brownlie et al., 1998), and the 
embryonic globin genes hemoglobin beta embryonic 3 (hbbe3) and hbbe1 (Ganis et al., 2012). WISH 
and qRT-PCR assays showed that the expression of these markers is comparable between morphants and 
control embryos at 24 hpf (Fig. 2B, C), thus confirming that primitive erythrocytes precursors are 
correctly generated. Starting from about 24-26 hpf erythroid progenitors differentiate in proerytrhroblasts 
and enter the circulation continuing the maturation process (Detrich et al., 1995; Weinstein et al., 1996; 
Chen and Zon, 2009). At 48 hpf hbbe3 and gata1 must be downregulated to allow primitive erythrocytes 
differentiation. Therefore, we analyzed the expression of these genes by WISH and qRT-PCR assays at 
48 hpf to verify the proceeding of the maturation process. WISH assays showed that hbbe3 and gata1 
are correctly downregulated in control embryos whereas they are still up-regulated in the 96% (n=25) 
and 89,47% (n=17) of etv6 morphant embryos respectively (Fig. 2D). We confirmed also by RT-PCR 
analysis that hbbe3 (FC = 2,17 p < 0,001) and gata1 (FC = 1,49 p < 0,01) are upregulated in etv6 
morphants, while alas2 is downregulated (FC = 0,46 p < 0,001; Fig. 2E). Overall, our findings strongly 
suggest that etv6 is not involved in the emergence of primitive erythrocytes precursors, whereas it is 
essential for primitive erythrocytes differentiation in zebrafish.  
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Figure 2: Primitive erythrocytes differentiation is impaired in etv6 morphants. Legend in the next page. 
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Figure 2: Primitive erythrocytes differentiation is impaired in etv6 morphants. (A) O-dianisidine staining 
highlights the reduction of hemoglobin in etv6 morphants at 48 hpf. (B, C) The expression of the primitive 
erythrocytes markers at 24 hpf, at the onset of erythrocytes differentiation, is comparable between controls and 
etv6 morphants suggesting that primitive erythrocyte precursors are correctly generated. (B) WISH assays of 
hbbe1, hbbe3 and gata1 genes at 24 hpf. (C) qRT-PCR assays alas2, hbbe3 and gata1 at 24 hpf. (D, E) The 
expression of hbbe3 and gata1 is abnormally upregulated in etv6 morphants at 48 hpf, while it is correctly 
downregulated in control embryos. (D) WISH assays of hbbe3 and gata1 genes at 48 hpf. (E) qRT-PCR assays 
alas2, hbbe3 and gata1 at 24 hpf; alas2 is downregulated in etv6 morphants. (A left, B, D) Lateral views; dorsal 
is up, anterior is left. (A right) ventral views, anterior is left. (E) t test: * = p < 0,05; ** = p < 0,01; *** = p < 0,001. 
 
 
A previous paper of our lab showed that the alteration of primitive erythrocytes differentiation can be 
caused by the increased activation of the Notch pathway leading to the upregulation of the Notch 
downstream target her6 in the PLM at about 10 somite stage (Bresciani et al., 2010). her6 is the zebrafish 
homologue of the mammalian gene HES1, which encodes a transcription factor that interacts with 
GATA1 both in vivo and in vitro and can inhibit erythroid/megakaryocytic differentiation by suppressing 
GATA1 activity (Ishiko et al., 2005). We therefore hypothesized that the alteration of primitive 
erythrocytes differentiation observed in etv6 morphants could be caused by the overexpression of her6. 
Hence, we analyzed her6 expression by WISH assays and we found that its hybridization signal is 
upregulated and expanded in 85,19% (n=27) of etv6 morphants compared to control embryos (Fig. 3A). 
To confirm that the alteration of primitive erythrocytes differentiation is caused by the increased activity 
of the Notch pathway, we tried to rescue the defective maturation observed at 48 hpf by treating etv6 
morphants with the Notch inhibitor DAPT starting from about 10 somites. O-dianisidine staining showed 
that the alteration of primitive erythrocytes differentiation is partially rescued in the 75% (n=40) of etv6 
morphants treated with 100M DAPT compared to untreated etv6-atg-MO injected embryos (Fig. 3B). 
Thus, the defective primitive erythrocytes maturation in etv6 morphants is, at least in part, caused by the 
increased activity of the Notch pathway. Furthermore, our results indicate etv6 as a potential modulator 
of the Notch pathway signaling in primitive erythrocytes. 
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Figure 3: etv6 is involved in the modulation of the Notch pathway. (A) Flat mount preparation of WISH assay 
showing the upregulation and the expansion of her6 expression in the posterior lateral mesoderm (arrowhead) of 
etv6 morphants at 8 somites. The detail of the PLM is shown. Dorsal view, anterior is up (B) The decreased o-
dianisidine staining observed in etv6 morphants is partially rescued by the treatment with 100M of the notch 
pathway inhibitor DAPT. Lateral views, anterior is left, dorsal is up. 
 
 
 
Recently, it has been reported that ETV6 mutations can alter the expression of KLF6 (Zhang et al., 2015). 
Since the zebrafish klf6a gene, along with klf1, klf3 and klf17 are involved in the differentiation of 
primitive erythrocytes (Gardiner et al., 2007; Fu et al., 2009; Xue et al., 2015), we thus decided to test 
by qRT-PCR analysis if etv6 knockdown can cause the alteration of these genes at 24 hpf and 48 hpf. At 
24 hpf the expression of klf3 (FC = 1,63 p < 0,001) and klf17 (FC = 1,61 p < 0,01) is significantly 
upregulated in etv6 morphants, while the expression of klf1 and klf6a is comparable between control and 
morphant embryos (Fig. 4). At 48 hpf klf3 (FC = 1,28 p < 0,05) and klf6a (FC = 1,37 p < 0,05) are slightly 
but statistically significant upregulated, whereas klf1 (FC = 4,64 p < 0,001) and klf17 (FC = 11,60 p < 
0,01) are strongly upregulated in etv6 morphants compared to control embryos (Fig. 4). 
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Figure 4: etv6 knockdown causes the upregulation of klf genes. At 24 hpf only klf3 and klf17 are upregulated 
in etv6-MO injected embryos. However, at 48 hpf all klf genes analysed are upregulated in etv6 morphants and 
among them klf1 and klf17 are the most strongly activated. t test: * = p < 0,05; ** = p < 0,01; *** = p < 0,001. 
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These results are consistent with the roles of klf genes in zebrafish primitive erythrocytes maturation. In 
fact, klf3, klf6a and klf17 knockdown determined the downregulation of hbbe3 (Gardiner et al., 2007; 
Xue et al., 2015), and we report that etv6 loss of function induced the upregulation of both klf genes and 
hbbe3. Moreover, klf1 in zebrafish is known to be involved in primitive erythropoiesis regulating 
globin gene, but in mammals KLF1 primarily regulates the adult β globin gene. Besides embryonic 
globin genes, Klf transcription factors control also the expression of multiple erythroid-specific genes, 
such as those involved in heme synthesis (Donze et al., 1995; Hodge et al., 2006; Pilon et al., 2006; 
Gardiner et al., 2007; Fu et al., 2009; Xue et al., 2015). Thus, etv6 could potentially influence several 
processes of erythrocytes differentiation via the modulation of klf genes expression. The notion that 
ETV6 is mainly known as a transcriptional repressor (Lopez et al., 1999; Chakrabarti and Nucifora, 
1999; Guidez et al.,2000), together with the upregulation of klf genes consequently to etv6 knockdown, 
lead us to speculate that Etv6 could directly repress klf genes transcription, maintaining the correct level 
of klf genes expression during primitive erythropoiesis. However, further experiments are needed to 
verify the direct interaction of Etv6 with the promoters of klf genes. 
Overall, our findings highlight the key role of Etv6 in the differentiation of primitive erythrocytes, 
exerted through the regulation of klf genes expression and the modulation of the Notch pathway 
signalling. 
 
Materials and methods 
 
Zebrafish lines and maintenance 
Zebrafish (Danio rerio) embryos were raised and maintained under standard conditions and national 
guidelines (Italian decree 4th March 2014, n.26). All experimental procedures were approved by IACUC 
(Institutional Animal Care and Use Committee). Zebrafish AB wild-type strains were obtained from the 
Wilson lab, University College London, London, United Kingdom. For in vivo observations and 
imaging, embryos beyond 24 hpf were washed, dechorionated and anaesthetized with 0.016% tricaine 
(ethyl 3-aminobenzoate methanesulfonate salt; Sigma-Aldrich) before observations and picture 
acquisition. Embryos were staged according to morphological criteria (Kimmel et al., 1995). 
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Whole mount in situ hybridization, embryo sectioning, o-dianisidine staining and imaging 
Whole mount in situ hybridizations were carried out as described (Thisse and Thisse, 2007). The 
riboprobes were synthesized using the Ambion® MAXIscript® SP6/T7 In Vitro Transcription Kit 
(Thermo Fisher Scientific). We synthesized probes as described in the following papers: gata1 (Detrich 
et al., 1995), hbbe1 and hbbe3 (Ganis et al., 2012), her6 (Pasini et al., 2001). To synthesize etv6 probe 
we amplified 877 bp of the coding sequence that we subcloned in the pGEM-T easy vector (Promega). 
The construct was then digested to synthesize antisense and sense probes. To amplify the sequence used 
for the synthesis of the probes we used the following primers: 
etv6-probe-fw  5’- CGCGAGGGGAACATTATCCA -3’ 
etv6-probe-rev 5’- AGGAGATACAGACAGCGGGT -3’ 
Images of stained embryos were taken on a Leica MZFLIII epifluorescence stereomicroscope equipped 
with a DFC 480 digital camera and LAS Leica imaging software (Leica, Wetzlar, Germany). Some of 
the hybridized embryos were then embedded in paraffin (Paraplast plus, Bio Optica) and sectioned (8m) 
on a microtome (Leitz 1516). The slides were mounted with Eukitt (Bio Optica) and all sections were 
observed using a Leica DM6000B microscope equipped with a DFC 480 digital camera and LAS Leica 
imaging software (Leica, Wetzlar, Germany). O-dianisidine staining was carried out as described 
(Detrich et al., 1995) 
 
Real-time quantitative PCR assay and semi-quantitative RT-PCR 
Total RNA was isolated from embryos at different developmental stages using the SV Total RNA 
isolation System kit (Promega, Madison, Wisconsin, USA). After treatment with DNase I RNase-free 
(Roche, Basel, Switzerland), 1 g of RNA was reverse-transcribed using the ImProm-II™ Reverse 
Transcription System (Promega) according to manufacturer’s instructions. Real-time analysis was 
performed on Light Cycler 480II with Universal Probe Master system (Roche Diagnostics; F. Hoffmann-
La Roche Ltd.). Primers and probes were selected according to the Software Probe Finder (Roche 
Diagnostics) and are reported in table below. Data were expressed using the comparative ΔΔCt method, 
using rpl8 gene as reference and ctrl-MO or GFP mRNA injected embryos as standardization control; 
both t test and SD values refer to triplicates of a single experiment and N=3 biological independent 
experiments were performed for each gene. 
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To assess the non-specific activation of p53, semi-quantitative RT-PCR were performed with cDNA 
obtained from etv6 morphants at 24hpf. p53 and 113-p53 were subjected to 20 or 25 amplification 
cycles using primers reported in (Robu et al., 2007). 
 
Gene name Primer sequence Probe number 
z_rpl8 fw tcaagggaatcgtgaaggac 82 
z_rpl8 rev gggtcacgaaacatcacctt 
z_alas2 fw aaaagctgctcaatcctctga 7 
z_alas2 rev tgccgctttggctctttat 
z_gata1 fw aacgacatcttcaatactacacttgc 82 
z_gata1 rev ggacacccaacgagaagg 
z_hbbe3 fw aagtcgacccaggcaattt 29 
z_hbbe3 rev tgcagtcatccagattaagacc 
z_klf1 fw acggatggctgtgactcaa 8 
z_klf1 rev cagatccagaaagcctttttca 
z_klf3 fw gctgagcccgtcactcac 18 
z_klf3 rev acgaagggtgtcagaacctg 
z_klf6a fw ttgccatcgcttgaagaata 78 
z_klf6a rev gtaaggctcgctctgcaaat 
z_klf17 fw ccacattttagacgagaagcagt 19 
z_klf17 rev tccacctcaataaggggtctc 
 
Morpholino microinjection 
Antisense morpholinos were purchased from Gene Tools (LLC, Philomath, OR). Morpholinos were 
diluted in Danieau solution (Nasevicius and Ekker, 2000) and injected into 1-to-2 cell-stage embryos 
using Eppendorf FemtoJet Micromanipulator 5171. Rhodamine dextran (Molecular Probes, Life 
technology) was co-injected as dye tracer. etv6 knockdown was performed injecting 0,5pmol/embryo of 
a translation blocking MO (etv6-MO 5’-CATGTCTCGTTGAAATTCAGGAAGT‑3’) previously 
described (Roukens et al., 2010). A standard control oligo (ctrl-MO, 5’-
CCTCTTACCTCAGTTACAATTTATA-3’, against human -globin gene) with no target in zebrafish 
embryos, was also used, to check for non-specific effects due to the injection procedure. Co-injection of 
etv6-MO with 0,75 pmol/embryo p53-MO was performed to abolish aspecific effects (Robu et al., 2007). 
 
  
 Brief Report  
96 
 
References 
 
Bertrand, J.Y., Cisson, J.L., Stachura, D.L., and Traver, D. (2010). Notch signaling distinguishes 2 waves 
of definitive hematopoiesis in the zebrafish embryo. Blood 115, 2777-2783. 
Bertrand, J.Y., Kim, A.D., Teng, S., and Traver, D. (2008). CD41+ cmyb+ precursors colonize the 
zebrafish pronephros by a novel migration route to initiate adult hematopoiesis. Development 135, 
1853-1862. 
Boccuni, P., MacGrogan, D., Scandura, J.M., and Nimer, S.D. (2003). The human L(3)MBT polycomb 
group protein is a transcriptional repressor and interacts physically and functionally with TEL 
(ETV6). J Biol Chem 278, 15412-15420. 
Bohlander, S.K. (2005). ETV6: a versatile player in leukemogenesis. Semin Cancer Biol 15, 162-174. 
Bresciani, E., Confalonieri, S., Cermenati, S., Cimbro, S., Foglia, E., Beltrame, M., Di Fiore, P.P., and 
Cotelli, F. (2010) Zebrafish numb and numblike are involved in primitive erythrocyte 
differentiation. PLoS One 5, e14296. 
Chakrabarti, S.R., and Nucifora, G. (1999). The leukemia-associated gene TEL encodes a transcription 
repressor which associates with SMRT and mSin3A. Biochem Biophys Res Commun 264, 871-
877. 
Chen, A.T., and Zon, L.I. (2009). Zebrafish blood stem cells. J Cell Biochem 108, 35-42. 
Detrich, H.W., 3rd, Kieran, M.W., Chan, F.Y., Barone, L.M., Yee, K., Rundstadler, J.A., Pratt, S., 
Ransom, D., and Zon, L.I. (1995). Intraembryonic hematopoietic cell migration during vertebrate 
development. Proc Natl Acad Sci U S A 92, 10713-10717. 
Donaldson, L.W., Petersen, J.M., Graves, B.J., and McIntosh, L.P. (1996). Solution structure of the ETS 
domain from murine Ets-1: a winged helix-turn-helix DNA binding motif. EMBO J 15, 125-134. 
Donze, D., Townes, T.M., and Bieker, J.J. (1995). Role of erythroid Kruppel-like factor in human 
gamma- to beta-globin gene switching. J Biol Chem 270, 1955-1959. 
Eguchi-Ishimae, M., Eguchi, M., Maki, K., Porcher, C., Shimizu, R., Yamamoto, M., and Mitani, K. 
(2009). Leukemia-related transcription factor TEL/ETV6 expands erythroid precursors and 
stimulates hemoglobin synthesis. Cancer Sci 100, 689-697. 
Fu, Y.F., Du, T.T., Dong, M., Zhu, K.Y., Jing, C.B., Zhang, Y., Wang, L., Fan, H.B., Chen, Y., Jin, Y., 
et al. (2009). Mir-144 selectively regulates embryonic alpha-hemoglobin synthesis during 
primitive erythropoiesis. Blood 113, 1340-1349. 
Fujiwara, Y., Browne, C.P., Cunniff, K., Goff, S.C., and Orkin, S.H. (1996). Arrested development of 
embryonic red cell precursors in mouse embryos lacking transcription factor GATA-1. Proc Natl 
Acad Sci U S A 93, 12355-12358. 
Galloway, J.L., Wingert, R.A., Thisse, C., Thisse, B., and Zon, L.I. (2005). Loss of gata1 but not gata2 
converts erythropoiesis to myelopoiesis in zebrafish embryos. Dev Cell 8, 109-116. 
Ganis, J.J., Hsia, N., Trompouki, E., de Jong, J.L., DiBiase, A., Lambert, J.S., Jia, Z., Sabo, P.J., Weaver, 
M., Sandstrom, R., et al. (2012). Zebrafish globin switching occurs in two developmental stages 
and is controlled by the LCR. Dev Biol 366, 185-194. 
Gardiner, M.R., Gongora, M.M., Grimmond, S.M., and Perkins, A.C. (2007). A global role for zebrafish 
 Brief Report  
97 
 
klf4 in embryonic erythropoiesis. Mech Dev 124, 762-774. 
Guidez, F., Petrie, K., Ford, A.M., Lu, H., Bennett, C.A., MacGregor, A., Hannemann, J., Ito, Y., 
Ghysdael, J., Greaves, M., et al. (2000). Recruitment of the nuclear receptor corepressor N-CoR 
by the TEL moiety of the childhood leukemia-associated TEL-AML1 oncoprotein. Blood 96, 2557-
2561. 
Hock, H., Meade, E., Medeiros, S., Schindler, J.W., Valk, P.J., Fujiwara, Y., and Orkin, S.H. (2004). 
Tel/Etv6 is an essential and selective regulator of adult hematopoietic stem cell survival. Genes 
Dev 18, 2336-2341. 
Hodge, D., Coghill, E., Keys, J., Maguire, T., Hartmann, B., McDowall, A., Weiss, M., Grimmond, S., 
and Perkins, A. (2006). A global role for EKLF in definitive and primitive erythropoiesis. Blood 
107, 3359-3370. 
Ishiko, E., Matsumura, I., Ezoe, S., Gale, K., Ishiko, J., Satoh, Y., Tanaka, H., Shibayama, H., Mizuki, 
M., Era, T., et al. (2005). Notch signals inhibit the development of erythroid/megakaryocytic cells 
by suppressing GATA-1 activity through the induction of HES1. J Biol Chem 280, 4929-4939. 
Jin, H., Xu, J., and Wen, Z. (2007). Migratory path of definitive hematopoietic stem/progenitor cells 
during zebrafish development. Blood 109, 5208-5214. 
Kissa, K., and Herbomel, P. (2010). Blood stem cells emerge from aortic endothelium by a novel type of 
cell transition. Nature 464, 112-115. 
Kwiatkowski, B.A., Bastian, L.S., Bauer, T.R., Jr., Tsai, S., Zielinska-Kwiatkowska, A.G., and 
Hickstein, D.D. (1998). The ets family member Tel binds to the Fli-1 oncoprotein and inhibits its 
transcriptional activity. J Biol Chem 273, 17525-17530. 
Lopez, R.G., Carron, C., Oury, C., Gardellin, P., Bernard, O., and Ghysdael, J. (1999). TEL is a sequence-
specific transcriptional repressor. J Biol Chem 274, 30132-30138. 
Murayama, E., Kissa, K., Zapata, A., Mordelet, E., Briolat, V., Lin, H.F., Handin, R.I., and Herbomel, 
P. (2006). Tracing hematopoietic precursor migration to successive hematopoietic organs during 
zebrafish development. Immunity 25, 963-975. 
Palis, J. (2014). Primitive and definitive erythropoiesis in mammals. Front Physiol 5, 3. 
Pilon, A.M., Nilson, D.G., Zhou, D., Sangerman, J., Townes, T.M., Bodine, D.M., and Gallagher, P.G. 
(2006). Alterations in expression and chromatin configuration of the alpha hemoglobin-stabilizing 
protein gene in erythroid Kruppel-like factor-deficient mice. Mol Cell Biol 26, 4368-4377. 
Poirel, H., Oury, C., Carron, C., Duprez, E., Laabi, Y., Tsapis, A., Romana, S.P., Mauchauffe, M., Le 
Coniat, M., Berger, R., et al. (1997). The TEL gene products: nuclear phosphoproteins with DNA 
binding properties. Oncogene 14, 349-357. 
Potter, M.D., Buijs, A., Kreider, B., van Rompaey, L., and Grosveld, G.C. (2000). Identification and 
characterization of a new human ETS-family transcription factor, TEL2, that is expressed in 
hematopoietic tissues and can associate with TEL1/ETV6. Blood 95, 3341-3348. 
Rasighaemi, P., Onnebo, S.M., Liongue, C., and Ward, A.C. (2015). ETV6 (TEL1) regulates embryonic 
hematopoiesis in zebrafish. Haematologica 100, 23-31. 
Rhodes, J., Hagen, A., Hsu, K., Deng, M., Liu, T.X., Look, A.T., and Kanki, J.P. (2005). Interplay of 
pu.1 and gata1 determines myelo-erythroid progenitor cell fate in zebrafish. Dev Cell 8, 97-108. 
 Brief Report  
98 
 
Robu, M.E., Larson, J.D., Nasevicius, A., Beiraghi, S., Brenner, C., Farber, S.A., and Ekker, S.C. (2007). 
p53 activation by knockdown technologies. PLoS Genet 3, e78. 
Roukens, M.G., Alloul-Ramdhani, M., Baan, B., Kobayashi, K., Peterson-Maduro, J., van Dam, H., 
Schulte-Merker, S., and Baker, D.A. (2010). Control of endothelial sprouting by a Tel-CtBP 
complex. Nat Cell Biol 12, 933-942. 
Takahashi, W., Sasaki, K., Kvomatsu, N., and Mitani, K. (2005). TEL/ETV6 accelerates erythroid 
differentiation and inhibits megakaryocytic maturation in a human leukemia cell line UT-7/GM. 
Cancer Sci 96, 340-348. 
Waga, K., Nakamura, Y., Maki, K., Arai, H., Yamagata, T., Sasaki, K., Kurokawa, M., Hirai, H., and 
Mitani, K. (2003). Leukemia-related transcription factor TEL accelerates differentiation of Friend 
erythroleukemia cells. Oncogene 22, 59-68. 
Wang, L.C., Kuo, F., Fujiwara, Y., Gilliland, D.G., Golub, T.R., and Orkin, S.H. (1997). Yolk sac 
angiogenic defect and intra-embryonic apoptosis in mice lacking the Ets-related factor TEL. 
EMBO J 16, 4374-4383. 
Wang, L.C., Swat, W., Fujiwara, Y., Davidson, L., Visvader, J., Kuo, F., Alt, F.W., Gilliland, D.G., 
Golub, T.R., and Orkin, S.H. (1998). The TEL/ETV6 gene is required specifically for 
hematopoiesis in the bone marrow. Genes Dev 12, 2392-2402. 
Weinstein, B.M., Schier, A.F., Abdelilah, S., Malicki, J., Solnica-Krezel, L., Stemple, D.L., Stainier, 
D.Y., Zwartkruis, F., Driever, W., and Fishman, M.C. (1996). Hematopoietic mutations in the 
zebrafish. Development 123, 303-309. 
Xue, Y., Gao, S., and Liu, F. (2015). Genome-wide analysis of the zebrafish Klf family identifies two 
genes important for erythroid maturation. Dev Biol 403, 115-127. 
Zhang, M.Y., Churpek, J.E., Keel, S.B., Walsh, T., Lee, M.K., Loeb, K.R., Gulsuner, S., Pritchard, C.C., 
Sanchez-Bonilla, M., Delrow, J.J., et al. (2015). Germline ETV6 mutations in familial 
thrombocytopenia and hematologic malignancy. Nat Genet 47, 180-185. 
  
 Brief Report  
99 
 
Supplementary figure S1 
 
 
 
Figure S1: etv6-MO induces the non-specific activation of 113-p53. (A) The injection of 0,5 
pmol/embryo of etv6-MO causes apoptosis in brain tissue and curved tail at 24 hpf. These alterations are 
rescued by the co-injection of 0,75 pmol/embryo of p53-MO along with etv6-MO. (B) Semi-quantitative 
RT-PCR performed at 24 hpf showing that etv6-MO injection induces the upregulation of 113-p53, 
encoding a truncated p53 isoform which is considered diagnostic for non-specific p53 activation caused 
by some morpholino molecules (Robu et al., 2007). Also the semi-quantitative RT-PCRs of p53 and 
actin are reported. actin amplification at 25 cycles is shown to compare the saturation level. 
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The Coiled-Coil Domain Containing 80 (ccdc80) gene regulates 
gadd45beta2 expression in the developing somites of zebrafish as 
a new player of the hedgehog pathway 
 
During my Ph.D., I have been also partecipated in the characterization of ccdc80 gene function in 
zebrafish development as side project. The Coiled-Coil-Domain Containing 80 (Ccdc80) gene, also 
named DRO1 in human (Down-Regulated by Oncogene 1), URB in mouse (Up-Regulated in BRS-3 
deficient mice), CL2 in rat (Clone 2), and equarin in chicken, has been recently suggested to be involved 
in different functions among vertebrates. Ccdc80 was first isolated in mice, where it is up-regulated in 
adipose tissue of obese BRS-3-deficient animals [1]. Moreover, Ccdc80 is highly expressed in mice white 
adipose tissue and its silencing inhibits adipocytes differentiation [2], suggesting a role in the regulation 
of body weight and energy metabolism. Ccdc80 is also expressed in mouse developing cartilage, 
suggesting a role during skeletogenesis [3] 
Human CCDC80 is almost ubiquitously expressed, with the highest levels in heart and skeletal muscles 
[4,5]. Furthermore, human CCDC80 can be considered a potential tumor suppressor gene [6]. In fact, it 
is strikingly down-regulated in thyroid neoplastic cell lines and tissues, as well as in colon and pancreatic 
cancer cell lines and in most colorectal cancer specimens [7], while its ectopic expression in these cell 
lines results in substantial inhibition of growth properties. The CCDC80 protein is highly conserved 
among vertebrates, and contains multiple signals of cellular compartmentalization and post-translational 
modifications. In particular, it has a N-terminus leader peptide for extracellular export and many nuclear 
localization signals [6]. In different studies, the CCDC80 protein has been identified in a N-glycosylated 
form and was suggested to be secreted. Rat, mouse and human CCDC80 show three PDUDES domains 
(Procaryotes- DRO1-URB-DRS-Equarin-SRPUL) which in human are correlated with a tumor 
suppressor role [8]. We have previously reported that in zebrafish there are three homologs of the human 
CCDC80gene [9]. The zebrafish ccdc80-l1 gene is expressed in muscular tissues, specifically in adaxial 
cells and muscle pioneers, which are both involved in axon pathfinding of motoneurons. Despite 
somitogenesis and myogenesis processes occurred properly in ccdc80-l1 knocked-down embryos, 
ccdc80-l1 loss of function impaired the proper axonal pathfinding, especially in ventral axons guidance. 
Furthermore, the analysis of ccdc80-l1 upstreamregulation revealed that the Hedgehog pathway 
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modulates its expression in territories involved in axonal guidance (Brusegan et al.,2012). Herein we 
show that zebrafish ccdc80 paralogue is strongly expressed in the notochord but it is not required for the 
correct formation of this structure. However, loss and gain of function experiments suggests that ccdc80 
is involved in somitogenesis process as a downstream effector of the Hedgehog pathway and as an 
upstream regulator of gadd45b2. 
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The Coiled-Coil Domain Containing 80 (CCDC80) gene has been identiﬁed as strongly induced in rat thyroid PCCL3 cells immortalized by the
adenoviral E1A gene. In human, CCDC80 is a potential oncosoppressor due to its down-regulation in several tumor cell lines and tissues and
it is expressed in almost all tissues. CCDC80 has homologous in mouse, chicken, and zebraﬁsh. We cloned the zebraﬁsh ccdc80 and
analyzed its expression and function during embryonic development. The in-silico translated zebraﬁsh protein shares high similarity with its
mammalian homologous, with nuclear localization signals and a signal peptide. Gene expression analysis demonstrates that zebraﬁsh ccdc80
is maternally and zygotically expressed throughout the development. In particular, ccdc80 is strongly expressed in the notochord and it is
under the regulation of the Hedgehog pathway. In this work we investigated the functional effects of ccdc80-loss-of-function during
embryonic development and veriﬁed its interaction with gadd45b2 in somitogenesis.
J. Cell. Physiol. 230: 821–830, 2015. © 2014 Wiley Periodicals, Inc.
In vertebrates muscles develop from the somites, bilateral pairs
of mesodermal segments ﬂanking the notochord
(Stemple, 2005). In zebraﬁsh (Danio rerio), somitogenesis
occurs between 10.5 hours post fertilization (10.5 hpf) and
24 hpf (Stickney et al., 2000). Somites are created sequentially
in an anterior to posterior sequence, concomitantly with the
posterior growth of the trunk and tail (Holley, 2007). Cells in
the presomitic mesoderm (PSM) alter their adhesive proper-
ties and undergomesenchymal to epithelial transitions, forming
somite pairs every 20–30min until a total of about 30 somites
(Stickney et al., 2000). Amolecular clock has been proposed for
the regulation of this reiterative process. The clock causes cells
in the PSM to undergo cyclical activation and repression of
several Notch pathway genes, such as her genes, a family of
transcriptional repressors (Oates et al., 2005; Echeverri and
Oates, 2007). Each cell in the PSM periodically makes and
degrades the products of these genes, in a synchronousmanner
with its neighbors. Soon after segmentation, morphologically
distinct somites are created via the generation of a boundary
between anterior and posterior somite halves. Many genes
behave as segment-polarity genes; they are localized in the
anterior or posterior half of the somite. For example, in
zebraﬁsh the two bHLH (basic-helix-loop-helix) transcription
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factors mesp-a and mesp-b are required for the speciﬁcation of
anterior and posterior identity within each segment (Sawada
et al., 2000). As somite polarity is established, morphological
segmentation occurs. Mutations that affect clock functions also
perturb segment polarity, with markers of anterior and
posterior half of the somite generally expressed in a
disorganized manner throughout the somitic mesoderm
(Durbin et al., 2000). In zebraﬁsh theGADD45 family members
gadd45b1 and gadd45b2 are expressed as paired stripes
adjacent to the neural tube in the anterior PSM region where
presomitic cells mature. The knock-down and over-expression
of gadd45b genes caused somite defects (Kawahara
et al., 2005).
The Coiled-Coil-Domain Containing 80 (Ccdc80) gene, also
named DRO1 (Down-regulated by Oncogene 1) and SSG1
(Steroid Sensitive Gene 1) in human, Urb in mouse (Up-
regulated in BRS-3 deﬁcient mice), Cl2 (Clone 2) in rat and
EQUARIN in chicken, has been recently suggested to be
involved in different functions among vertebrates. Ccdc80 was
ﬁrst isolated in mice (Aoki et al., 2002), where it is up-regulated
in adipose tissue of obese BRS-3-deﬁcient animals and it was
suggested to play a role in the regulation of body weight and
energy metabolism (Tremblay et al., 2009). Moreover, murine
Ccdc80 is expressed in the developing cartilage, suggesting a
role during skeletogenesis (Liu et al., 2004). In chickens, two
alternative splicing forms of CCDC80 are described: S- and L-
EQUARIN. During embryogenesis, both transcripts are
detected in the developing lens, with a high dorsal to ventral
gradient. Microinjection of equarin mRNAs in xenopus
embryos induced abnormal eye development, suggesting its
involvement in eye formation (Mu et al., 2003). Human
CCDC80 is almost ubiquitously expressed, with the highest
levels in heart and skeletal muscle (Visconti et al., 2003). Studies
of expression proﬁling show that CCDC80 is expressed also in
skeletal myotubes during normal differentiation of skeletal
muscles (Raymond et al., 2010), and in muscles from patients
with Duchenne dystrophy (Tseng et al., 2002; Haslett
et al., 2003). In skeletal myotubes its expression is elicited by
pyruvate (Wilson et al., 2007) and suppressed by starvation
(Stevenson et al., 2005), suggesting a possible role for CCDC80
as a cell differentiation protein both in cultured cells andmuscle
tissues undergoing regeneration or remodeling.
Human CCDC80 is also considered a potential tumor
suppressor gene (Visconti et al., 2003; Ferraro et al., 2013), as it is
strikingly down-regulated in thyroid neoplastic cell lines and
tissues, in colon and pancreatic cancer cell lines and in most
colorectal cancer specimens (Bommer et al., 2005). Further
evidences of its involvement in tumors came from observation of
CCDC80 signiﬁcant down-regulation in transgenic mouse mam-
maryepithelial cells over-expressing theoncogeneAIB1 (Ferragud
et al., 2011). The encoded CCDC80 protein is highly conserved
among vertebrates, and contains multiple signals of cellular
compartmentalization and post-translational modiﬁcations. In
particular, it has a N-terminus leader peptide for extracellular
export andmanynuclear localization signals (Visconti et al., 2003).
Moreover, the CCDC80 protein has been identiﬁed in a N-
glycosylated secreted form and may be secreted. Studies of rat
Ccdc80 cellular localization resulted in two different sub-cellular
localization patterns: juxtanuclear, indicating a Golgian local-
ization, and nuclear-cytoplasmic (Visconti et al., 2003; Ferraro
et al., 2013). Indeed, human CCDC80 protein has been identiﬁed
both in aN-glycosylated secreted form (Bommer et al., 2005) and
in a nuclear form (Wang et al., 2013).
Human CCDC80 shows high sequence identity with its
homologous in rat (84%), mouse (83%), and chicken (66%). In
all species studied, the protein is highly basic and shows a lysine-
and a threonine-rich region. Moreover, three P-DUDES
domains (Procaryotes-DRO1-URB-DRS-Equarin-SRPUL) are
present. In human, P-DUDES are correlated with a tumor
suppressor role and are found in single copy also in SRPX and
SRPX2 proteins, which are involved in tumor suppression and
progression respectively (Pawlowski et al., 2010).
In this work, we investigated the function of ccdc80 in-vivo,
during the embryonic development of zebraﬁsh bymeansof loss-
and gain-of-function experiments. Our results suggest a new
functional role for the zebraﬁsh homologous ccdc80 during
somitogenesis as a downstream effector of the Hedgehog
signaling (Hh), and as an upstream regulator of gadd45b2.
Materials and Methods
Animals
Breeding zebraﬁsh were maintained at 28°C on a 14 h light/10 h
dark cycle. Embryos were collected by natural spawning, staged
according to Kimmel and colleagues (Kimmel et al., 1995) and
raised at 28°C in ﬁsh water (Instant Ocean, 0,1% Methylene Blue)
in Petri dishes, according to established techniques, in agreement
with EU Directive 2010/63/EU for animal welfare. We express the
embryonic ages in somites (s) and hours post fertilization (hpf). AB
strains were obtained from the Wilson lab (University College of
London, London, United Kingdom).
Isolation and cloning of the zebraﬁsh ccdc80 gene
The putative zebraﬁsh ccdc80 ORF sequence was identiﬁed
through in-silico search of the ENSEMBL zebraﬁsh assembly
version 9 (Zv9) using rat Ccdc80 (Cl2) gene sequence previously
described (Visconti et al., 2003). The zebraﬁsh putative ORF was
fully contained in the RP71–20I5 clone, linkage group 9 (GenBank
Accession Number AL590146). The presumptive ORF of the
zebraﬁsh ccdc80 was ampliﬁed by means of reverse transcription
polymerase chain reaction (RT-PCR) performed on total RNA
isolated from adult ﬁsh. The ccdc80 entire coding sequence was
cloned in the pCS2þ vector with the following primers:
ccdc80_ sense: 50-TAGAATTCGCCACCATGAGGGCAC-30;
ccdc80_ antisense: 50-ATAGAGCTCGAGCTAATATCC
ATAACCCTGATGATAAC-30. Cloning of the 50 and 30 UTR
(Untranslated Region) of ccdc80 gene was performed using the 50/30
RACE kit, 2nd Generation (Roche) following manufacturer's
instructions, on the basis of the RP71–20I5 clone.
Following primers for the 50 end and for the 30 end cloning were
used:
50_ccdc80_sense: 50-GCGAATTCGATTTGTCTTTGTTAA
AAACTAT–30, 50_ccdc80_antisense: 50-GACGCCAGTAG
TTTGGAGAACC-30; 30_ccdc80_sense: 50–GGCCATCCA
GCAGTCTCTAGG-30, 30_ccdc80_antisense 50–TAAGGA
TCCGACCACGCGTATCGATGTCGAC-30.
Primers for RACE reactions were designed using the
Primer3 software program on the basis of the RP71–20I5 clone
sequence.
Analysis of the zebraﬁsh Ccdc80-encoded protein
Physical-chemical properties of the zebraﬁsh Ccdc80 protein were
in-silico deducted with the software program Compute pI/Mw
(Gasteiger et al., 2003). The putative sub-cellular localization of the
zebraﬁsh Ccdc80 protein was predicted using the software
program WoLF PSORT (Horton et al., 2007). Analysis of post-
translational glycosylation sites were performed using the available
tools on the web proteomics server Expasy, http://expasy.org/
tools/#proteome (Gupta and Brunak, 2002; Gasteiger et al., 2003;
Julenius et al., 2005). The presence of common motifs in the
Ccdc80 protein was analyzed with the MEME Suite Motif-based
sequence analysis tools (version 4.6.0) http://meme.nbcr.net
(Bailey and Elkan, 1994; Bailey and Gribskov, 1998). Alignment of
the three obtained domains was performed with the software
program ClustalW2, http://www.ebi.ac.uk/Tools/msa/clustalw2/
(Chenna et al., 2003; Larkin et al., 2007).
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RNA isolation
For extraction of total RNA, zebraﬁsh embryos at different
developmental stageswere snap frozen in liquid nitrogen and stored
at 80°C until further processing. Organs were dissected under a
stereomicroscope, frozen in liquid nitrogen and stored at 80°C
until further processing. Frozen specimens were homogenized in
TRIZOL (Invitrogen, Carlsbad, CA) and RNA was then puriﬁed
according to standard protocols.
Semi-quantitative RT-PCR
0.5mg of total RNA was used as a template for a reverse
transcription reaction with random primers and AMW-Reverse
Transcriptase (Roche Diagnostics Co, Indianapolis, IN). The
obtained cDNA (diluted 1:10) was used in a 50ml PCR reaction
(Taq DNA Polymerase, Eppendorf), which was stopped in the
exponential phase (25 cycles). To normalize, the elongation factor 1
alpha (ef1a) gene was also ampliﬁed in a parallel semi-quantitative
PCR.
Following primers were used:
ccdc80_sense: 50-CCAGGATCTCATCATGGAGC–30;
ccdc80_antisense: 50-GACCAGCTTCAGCACGGACA-30;
ef1a_sense: 50-GGTACTTCTCAGGCTGACTGT–30;
ef1a_antisense: 50-CAGACTTGACCTCAGTGGTTA–30.
10ml of each PCR reaction were loaded on an agarose gel and
blotted on a nylon Zeta-Probe GT membrane (Biorad, Hercules,
CA), hybridized with cloned DNA probes covering the full-length
ORF of the genes labeled with [a32P]dCTP (Random Primed
DNA Labeling Kit, Roche, RocheDiagnostics Co, Indianapolis, IN).
After hybridization, blots were exposed to a T-MAT G/RA
(Kodak) ﬁlm for 20min. Band densitometry was performed with
the Quantity One software program, Bio-Rad Laboratories, Inc.
Injections
Injections were carried out on 1- to 2-cell stage embryos; when
necessary the dye tracer rhodamine dextran (Molecular Probes,
Eugene, OR) was also co-injected. To block ccdc80 mRNA
translation, an ATG- (ccdc80-MO1) and a pre-ATG-ccdc80-MO
(ccdc80-MO2) targeting morpholinos were synthesized (Gene
Tools, LLC, Philomath, OR):
ccdc80-MO1: 50-AACCAAGCATATACCGTGCCCTCAT-30;
ccdc80-MO2: 50-GCCCTCATGTTTGAACAATTTAATA-30. and
used at the concentration of 1,5 pmole/embryo (12 ng) in 1
Danieau buffer (pH 7,6) as previously reported (Nasevicius and
Ekker, 2000). As a control for unspeciﬁc effects, we injected a
standard control morpholino oligonucleotide that has no target in
zebraﬁsh (ctrl-MO, Gene Tools). A ccdc80 50-mismatch mor-
pholino (ccdc80-mismatch-MO1, Gene Tools), designed against
the same region of ccdc80-MO1 was used as the control for
unspeciﬁc effect.
ccdc80-mismatch-MO1 50-AAgCAAcCATATAgCGT
GCgCTgAT-30.
The in-vivo test of the speciﬁcity was carried out as described in
Brusegan and colleagues (Brusegan et al., 2012). In brief: 300 pg/
embryo of the pCS2þ -ccdc80-MO1-GFP sensor plasmid have
been injected alone or co-injected with 12 ng/embryo of ccdc80-
MO1. The presence/absence of the GFP signal has been monitored
under a ﬂuorescent microscope at 20 s stage. ccdc80-MO1 cDNA
fragments inserted in the BamHI site were obtained using the
following complementary oligos:
ccdc80-MO_sense: 50 gatcATGAGGGCACGGTATATGCT
TGGTTCA 30; ccdc80-MO_antisense: 50 gatcTGAACCAAGC
ATATACCGTGCCCTCAT30.
For the rescue of the ccdc80-MO1 phenotype, 12 ng of ccdc80-
MO1 were injected together with 300 pg/embryo of ccdc80 full
length mRNA. gadd45b2 mRNA was synthesized from plasmid
kindly provided by Igor Dawid (Laboratory of Molecular Genetics,
National Institute of Child Health and Human Development,
National Institute of Health, Bethesda, MD). shh mRNA has been
kindly provided by Paolo Sordino (Laboratory of Cellular and
Developmental Biology, Stazione Zoologica AntonDohrn, Naples,
Italy). In over-expression experiments we have used 300 pg/
embryo of ccdc80 mRNA, 200 pg/embryo of gadd45b2mRNA and
300 pg/embryo of shh mRNA respectively. The control for
unspeciﬁc effects of over-expression experiments was performed
with the parallel injection of the same amount of gfp mRNA.
In-situ hybridization and histological analysis
Whole mount In-Situ Hybridization (WISH) experiments were
carried out as described by Thisse and colleagues (Thisse
et al., 1993). Embryos were ﬁxed for 2 h in 4% paraformaldehyde/
phosphate buffered saline, then rinsed with PBS-Tween, dehy-
drated in 100% methanol and stored at20°C until processed for
WISH (Jowett and Lettice, 1994). Antisense riboprobes were
previously in-vitro labelled with modiﬁed nucleotides (digoxigenin,
Roche). myod probe was prepared as described in E. Schnapp and
colleagues (Schnapp et al., 2009); mesp-a, her1, gadd45b1, and
gadd45b2 plasmids were a kind gift from I. Dawid. gsc, ntla, and shh
plasmids were a kind gift from P. Sordino. To synthesise the ccdc80
probe, the same primers were used as for the RT-PCR.
For histological sections, stained embryos were re-ﬁxed in 4%
PFA, dehydrated and stored in methanol, wax embedded and
sectioned (5mm).
Images of embryos and sections were acquired using a
microscope equipped with a digital camera with LAS Leica imaging
software (Leica,Wetzlar, Germany). Images were processed using
the Adobe Photoshop software and when necessary, different
focal planes of the same 3D image have been taken separately and
later merged in a single image.
Cyclopamine treatment
For the inhibition of the Hh pathways, embryos were exposed to
50mM cyclopamine (Sigma-Aldrich, Inc, St. Louis, MO) from
50% epiboly stage up to ﬁxation in PFA at 12–15 s stage.
Cyclopamine was dissolved in embryo medium and 0.5%
ethanol. Controls consisted of corresponding incubations in
0.5% ethanol in embryo medium (Barresi et al., 2000).
Results
Molecular cloning and in-silico analysis of the zebraﬁsh
ccdc80
In-silico search for the zebraﬁsh ccdc80 gene with the rat
Ccdc80 (Cl2) virtual probe allowed the identiﬁcation of exon
homologous sequences in the genomic Danio rerio database
(Zv9). The RT-PCR from the presumptive ATG to the stop
codon, ampliﬁed a cDNA of 2604 bp in length. The sequence
analysis of this product revealed only one ORF. The 50 (189 bp)
and 30 (133 bp) UTR sequences were ﬁnally obtained by RACE.
The 50 ending of the gene did not show further alternative
starting codons located in frame with the putative ORF. The
ﬁnal zebraﬁsh ccdc80 mRNA sequence (2926 bp) has been
deposited in the Genbank database with the Accession
Number EU269066 (GI:166831573).
ccdc80 cDNA codes for a protein of 867 amino acids in
length. Zebraﬁsh Ccdc80 is a highly basic protein (pI 9.68) and
has a predictedmolecular mass of 99.92 kDa. Sequence analysis
shows a putative signal peptide andmultiple nuclear localization
signals. Moreover, it shows a putative endoplasmic reticulum
retention signal at N-terminus (RARY), putative N-
glycosylation sites and several mucin-type-O-glycosylation
sites in a threonine-rich region from approximately amino acid
303–369 (Fig. 1A). Based on these results it is likely that the
protein is post-translationally modiﬁed and can have both
nuclear and cytoplasmatic localization. Moreover, along the
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protein three clusters of sequences occurs with the following
consensus sequences:
SLANFLASFAWKNRLWVISAPHAENWMYVQQMSAL
NEQFCC, FFMVLVDKDLNVKQWYPYPMW and MEIMYDLI
DQFQIRIQEMIIQKGFGMRCK; the alignment of the three
domains (146, 151, and 149 amino acids in length, respectively)
shows anoverall identity of 26%and a similarity of 43% (Fig. 1B–C).
The entire zebraﬁsh Ccdc80-encoded protein shares high
sequence identity with human DRO1 (56% identity, 69%
similarity), mouse Urb (55% identity, 68% similarity), rat Cl2
(54% identity, 68% similarity), and chicken L-EQUARIN (59%
identity, 71% similarity) (Suppl. Fig. 1). A previous description
and the alignment of the predicted zebraﬁsh proteins Ccdc80
(Chr9:35,060,460–35,084,513), Ccdc80-like1 (ccdc80-l1,
Chr6:16,322,724–16,342,517) and Ccdc80-like2 (ccdc80-l2,
Chr21: 18,662,129–18,669,986) has been performed by
Brusegan and colleagues (Brusegan et al., 2012).
Expression pattern of the zebraﬁsh ccdc80 gene in the
adult ﬁsh and during embryonic development
Semi quantitative RT-PCR analysis on RNA extracted from
organs of the adult ﬁsh (Fig. 2A) showed that ccdc80 is
expressed in all the analyzed tissues. In particular, it was
expressed at the highest level in the heart, and at the lowest in
the liver and intestine. Intermediate levels were evident in the
brain, in the ovarian and surrounding adipose tissue, in the
mesonephric duct, swim bladder, and pancreas.
Semi-quantitative temporal expression proﬁle of ccdc80 in
zebraﬁsh embryos at different developmental stages, showed
the presence of the transcript from the early blastula up to 48
hours post fertilization (48 hpf) (Fig. 2B). In particular, ccdc80
expressionwas decreased during gastrulation, presented a new
peak of expression during somitogenesis, and maintained
constant levels later in the development.
Spatial expression of ccdc80 mRNA analyzed by WISH in
pre-gastrulation (1–2, 4–8, 512–1000 cells) and gastrulation
developmental stages (30%–70% epiboly) showed a diffuse
pattern (Suppl. Fig. 2). From the 12-somite stage (12 s) to
48 hpf, ccdc80 transcript was only detected in the entire
notochord (Fig. 2C–H). Consistently with the semi quantitative
RT-PCR analysis, transient expression appeared in the heart at
48 hpf (Fig. 2H–I).
ccdc80 is positively regulated by the Hedgehog (Hh)
pathway
Considering the expression of ccdc80 in the notochord, we
decided to analyze its possible interaction with Hedgehog (Hh)
pathway, that is one of themain pathways in the notochord that
inﬂuences muscle differentiation (Echelard et al., 1993; Marti
et al., 1995), and that is able to induce sclerotome and muscles
in the absence of the notochord (Fan et al., 1995; Munsterberg
et al., 1995). The blockage of Hh signaling in wild-type embryos
treated from early cleavage stages with cyclopamine (Incardona
et al., 1998; Barresi et al., 2000) (65%, N¼ 95; Figs. 3A–B and
D), or in syu mutant embryos (Karlstrom et al., 1999) (70%
N¼ 30, Fig. 3D) produced an inhibition of ccdc80 expression in
the notochord in comparison to controls (0%, N¼ 50; Fig. 3D).
Conversely, the over-expression of the synthetic shhmRNA at
Fig. 1. Zebrafish Ccdc80 protein structure and motif analysis. (A) Image is displayed with the software PROSITE tool MyDomains - Image
Creator. SP: Signal Peptide, CL: cleavage site, NLS: Nuclear Localization Signals, D1, D2, D3: domains, Thr: Threonin rich region. (B) Position
of the three motifs (M1, M2, and M3) in the human DRO1, mouse Urb, rat Cl2, chicken EQUARIN-L, and zebrafish Ccdc80 homologous
proteins. (C) Alignment of the zebrafish Ccdc80 D1, D2, D3 domains. Color legend: red, small, hydrophobic, and aromatic (-Y) residues; Blue,
Acidic residues; Magenta, Basic residues; Green, Hydroxyl, Amine, Basic (-Q) residues. Consensus symbols: “*” identical residues in all
sequences; “:” conserved substitutions; “.” semi-conserved substitutions.
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1-to-2 cell stage, induced ccdc80 up-regulation in this structure
(59%, N¼ 89; Fig. 3C, D). These results show a relationship
between ccdc80 and Hh pathway, in particular ccdc80 appears
to be an Hh downstream effector.
ccdc80 loss-of-function affects zebraﬁsh
somite formation
To determine the role of ccdc80 during zebraﬁsh development,
we performed the knock-down of ccdc80 by means of the
injection of a speciﬁc antisense oligonucleotide morpholino
designed against the start site (ccdc80-MO1, Gene Tools). In all
the experiments, ccdc80-MO-injected embryos were
compared to embryos at the same developmental stage,
injected with the same amount of a non-speciﬁc control MO
(ctrl-MO). At 15 s, the majority of ccdc80-MO1 injected
embryos (75%; N¼ 150) displayed defects in the forming
somites, such as the loss of their proper morphology and
position, in comparison to control embryos (2%; N¼ 140,
Figs. 4A–C). Although at 24 hpf the differentiated somites
partially recovered their proper morphology and the embryos
were normally moving, 64.5% of ccdc80-MO injected embryos
(N¼ 124, Fig. 4E) showed curved tails compared to controls
(1%, N¼ 90, Fig. 4D). For testing the in-vivo efﬁciency of
ccdc80-MO1, 300 pg/embryo of the pCS2/GFP, containing the
ccdc80 target site of ccdc80-MO fused with the gfp ORF were
co-injected with 12 ng of ccdc80-MO or ctrl-MO respectively
(Fig. 4F–F'). The GFP signal was monitored under a ﬂuorescent
microscope at 20 s stage. The reduction of the GFP signal in the
majority (98%; N¼ 81) of the embryos co-injected with
ccdc80-MO1 and pCS2/GFP (Fig. 4G–G') indicated that ccdc80-
MO1 efﬁciently binds to its target region in-vivo.
In parallel we performed loss-of-function experiments with a
second morpholino (ccdc80-MO2, Gene Tools) designed in the
5'UTR, in apre-ATGregion. Injectionwith12ng/embryoof ccdc80-
MO2 gave the same defects in somite formation as ccdc80-MO1,
conﬁrming the speciﬁcity of the loss-of-function phenotype (70%;
N¼ 130, Fig. 4C).Moreover, the injectionof a ccdc80-5'-mismatch-
MOdid not produce any phenotype.Wewere also able to partially
rescue the phenotype co-injecting the ccdc80-MO1 with 300pg/
embryo of ccdc80 full-length mRNA (30%; N¼ 230, Fig. 4C).
To address whether the observed somite malformations
might be due to defects in gastrulation, we analyzed the
expression pattern of critical markers of convergence and
extension processes such as goosecoid (gsc) expressed in the
shield area (Thisse et al., 1994) (Suppl. Fig. 3A–B), and no tail a
Fig. 2. Expression of ccdc80 analyzed by semi quantitative RT-PCR and WISH. (A) Semi quantitative RT-PCR performed on different adult
tissues (A) and embryonic stages (B); the expression of ccdc80 and ef1a are shown. In (A) Lanes are: heart (lane 1), swim bladder (lane 2),
pancreas (lane 3), liver (lane 4), intestine (lane 5), brain (lane 6), mesonephric duct (lane 7), ovary (lane 8). In (B) lanes are 1–2 cells (lane 1),
4–8 cells (lane 2), 128 cells (lane 3), 1000 cells (lane 4), 30% epiboly (lane 5), 50% epiboly (lane 6), 75% epiboly (lane 7), 1–3 somites (lane 8), 16
somites (lane 9), 22 somites (lane 10), 24 hpf (lane 11) 48 hpf (lane 12). (C–I) WISH performed on zebrafish embryos at several stages of
development. (C–E) Starting from somitogenesis, ccdc80 is expressed in the notochord (C and E, arrow), as better shown by the histological
section of the trunk at 12 somites stage (arrow in D). The same hybridization signal persists also at 24 hpf (F and histological section G, arrow)
and 48hpf (H, arrow). At 48hpf, ccdc80 is also expressed in the heart (H and I, arrowhead). (C, E, F, H) Later views, dorsal is up. (D, G)
Transversal sections of the trunk, dorsal is up. (I) Frontal view of the head, dorsal is up. Scale bar indicated 100mm.
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(ntla) expressed in the notochord (Schulte-Merker et al., 1994)
(Suppl. Fig. 3C–D). Although ccdc80 is expressed in a diffuse
pattern during gastrulation (Suppl. Fig. 2D) and in the whole
notochord during segmentation (Fig. 3C–H), ccdc80-loss-of-
function experiments did not affect the expression of these
markers.
According to our previous demonstration of ccdc80
regulation by Hh pathway, we decided to investigate whether
the opposite effect also exists, by analyzing shh expression
pattern in ccdc80-MO1 injected embryos. shh transcript was
correctly expressed in all territories of ccdc80-loss-of-function
embryos (Suppl. Fig. 3E–F), suggesting the lack of a feed-back-
loop regulation effect.
ccdc80 loss-of-function perturbs the expression of
markers of somitogenesis and myogenesis
To better characterize the molecular events underlying the
somite defects observed in ccdc80-loss-of-funtion embryos, we
examined the expression of genes implicated in somitogenesis
and subsequent myogenesis. The ﬁrst step in somite formation
is the segmentation-clock that creates oscillations in gene
expression in the PSM and allows somite primordium
maturation. Several genes are expressed in the segmentation-
clock period; among them critical markers are her1 (Holley
et al., 2000) and mesp-a (Durbin et al., 2000; Sawada
et al., 2000). In ccdc80-loss-of-function embryos, her1 (Fig. 5A–
B, 80%, N¼ 60) and mesp-a (Fig. 5C–D, 70%, N¼ 60)
expressions were affected, showing irregular asymmetric
patterns and/or broader domains rather than the deﬁned
territories present in control embryos at the same devel-
opmental stages. Furthermore, in ccdc80-MO injected em-
bryos, themyogenicmarkermyodwas present but disorganized
in the paraxial mesoderm, reﬂecting upstream defects in
somitogenesis (Fig. 5E–F, 81% N¼ 60).
The cell cycle controllers gadd45b1 and gadd45b2 genes
have also been reported to control segmentation process
and somite development (Kawahara et al., 2005). For this
reason, we decided to investigate their expression in control
and ccdc80-loss-of-function embryos. gadd45b2 expression
was almost completely abolished in paraxial mesoderm in
most of the ccdc80-MO1 injected embryos (90%; N¼ 88,
Fig. 5G–H') while it was invariant in the PSM and Lateral Plate
Mesoderm (LPM) domains (Fig. 5G–H'). On the contrary,
gadd45b1 expression was not signiﬁcantly changed in
ccdc80-loss-of-function embryos (data not shown). We were
also able to rescue the ccdc80-loss-of-function phenotype:
the co-injection with 200 pg/embryo of gadd45b2 full-length-
mRNA partially rescued both the ccdc80-MO1 induced
alterations of somite structures and the myod expression at
8–10 s stage (30%; N¼ 55, Suppl. Fig. 4A–C'). Interestingly,
ccdc80 mRNA overexpression caused the opposite effect: an
enlargement of gadd45b2 paraxial mesoderm expression
domain in the majority (60%; N¼ 70, Fig. 5I–I') of injected
embryos, and an ectopic gadd45b2 expression in non-
mesodermal territories such as neural tube (Fig. 5I–I').
Moreover, we observed a decreased or absent gadd45b2
expression in LPM territories, while PSM was unaltered
(Fig. 5I–I').
The modulation of the Hedgehog pathway affects
gadd45b2 expression
To examine whether the interaction between Hh pathway and
ccdc80 in the notochord has an effect on the regulation of
gadd45b2 in the somites, we analyzed gadd45b2 expression in
Fig. 3. shh regulates ccdc80 expression. (A–C) In comparison with control embryos (A), cyclopamine treatment strongly down-regulated
ccdc80 expression in the notochord (B, asterisks), whereas injection of shhmRNA led to its up-regulation (C). (D) Different classes of embryos
with an altered Hh signaling (ctrl, cyclopamine treated, syumutants, shhmRNA injected), were analyzed for the expression levels of ccdc80 in
the notochord. (A–C) Dorsal views, rostral on the left. n: notochord. Scale bar indicated 100mm.
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embryos inhibited in the Hh pathway. Interestingly, the
inhibition of the Hh pathway with cyclopamine treatment,
resulted in a depletion of gadd45b2 expression in the paraxial
mesoderm (Fig. 6A–B'), as previously shown in ccdc80-loss-of-
function embryos (Fig. 5H–H'). Conversely, the expression of
gadd45b2 in the PSM was unaltered.
Discussion
Somitogenesis is a developmental process by which the
vertebrate trunk is divided into a series of segments termed
somites. In zebraﬁsh, somites form in an anterior to posterior
progression from the unsegmented PSM. This process requires
a segmentation clock that comprises oscillations in gene
expression in individual cells within the PSM. The coordination
of these mechanisms is guaranteed by several molecular
pathways; among them a pivotal role is played by the Hedgehog
signaling secreted by the notochord (Lewis et al., 1999; Wolff
et al., 2003). Mutants lacking the notochord often present
somitogenesis defects (reviewed by Stickney et al., 2000) and
modulation of Shh protein affects the proper formation of
somites and muscles (reviewed by Ingham and Kim, 2005). In
zebraﬁsh ccdc80 is expressed during gastrulation and, by the
time the somites are formed and speciﬁed, in the notochord. Its
Fig. 4. Loss-of-ccdc80 function affect somitogenesis in-vivo. (A–B) ccdc80-MO injected embryos (B) displayed enlarged and disorganized
somites in comparison to control embryos (A). Smaller, supernumerary somites are visible in ccdc80-MO injected embryos (arrow in B). (C)
Number of embryos showing somite defects following ccdc80-mis-regulation (ccdc80-MO1, ccdc80-MO2, and rescue), in comparison to
controls at 15 s. (D–E) ccdc80-MO injected embryos (arrow, E) displayed a curved tail in comparison to control embryos at 24 hpf (arrow, D).
(F, G') The pCS2þ construct containing the sequence recognized by the ccdc80-MO fused with the gfp open reading frame is used for injection
experiments with ctrl-MO or with the ccdc80-MO. (F–F') Embryos at 20 s stage: GFP-positive cells in the trunk and in the yolk epithelium
following co-injection of the sensor and the control-MO. (G–G') The absence of GFP when the sensor is co-injected with ccdc80-MO confirms
the efficiency of morpholino to target the ccdc80-ATG region. In F and G embryos are visualized under normal light, in F' and G' under
fluorescent light. (A–B) Dorsal views, rostral to the left. (C–D) Lateral views, rostral to the left. Scale bars indicated 100mm.
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function is not fundamental for notochord development, as
injection of ccdc80morpholino did not impair the formation of
medial structures. Moreover, despite its zygotic expression,
ccdc80 is not required during gastrulation as shown by the
proper expression of the organizer gene gsc and the
mesodermal marker ntla. By converse, ccdc80-MO injected
embryos displayed severe defects during somitogenesis,
suggesting that ccdc80 might be secreted from the notochord.
Indeed, Ccdc80 protein shows a signal peptide besides nuclear
localization signals that may allow its secretion and internal-
ization respectively. Investigation on Ccdc80 cellular local-
ization in zebraﬁsh is still needed, whereas several studies
already indicated human, rat, mouse and chicken homologous
as secreted proteins (Mu et al., 2003; Visconti et al., 2003; Liu
et al., 2004; Bommer et al., 2005; Ferragud et al., 2011). Analysis
of the expression patterns of different markers of somito-
genesis in ccdc80-loss-of-function embryos conﬁrmed that
somites lost their proper pattern. In particular, synchronization
of molecular clock oscillations seemed to be lost, as the
expression of her1 resulted asymmetric and disorganized.
Consequently, the expression pattern of the down-stream
markers mesp-a and myod resulted altered. The phenotype
Figure 5. ccdc80 loss-of-function perturbs the expression of markers of somitogenesis and myogenesis. (A–D) Expression of the molecular
clock genes her1 (A–B) and mesp-a (C–D) were altered in ccdc80-loss-of-function embryos in comparison to controls at the same
developmental stage. The myogenic marker myod (E–F) was disorganized in ccdc80-injected embryos, reflecting previous defects in
somitogenesis. gadd45b2 expression resulted almost completely abolished in the paraxial mesoderm of ccdc80-MO injected embryos (H–H',
asterisks) in comparison to controls (G–G'). ccdc80 mRNA over-expression caused the opposite effect with a broader gadd45b2 expression
domain also in ectopic position in non-mesodermal territories (I-I', black arrows) and a decreased signal in the LPM (I–I', white arrowheads).
(A–F) Dorsal views, rostral to the left. (G, H, I) Dorsal view, head is up. (G', H', I') Transversal sections of the trunk, dorsal is up. LPM: lateral
plate mesoderm, nt: neural tube, S: somites. Scale bars indicated 100mm.
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displayed by ccdc80-MO injected embryos is recovered later in
development and motility returns close to normality at 24 hpf.
Hence, ccdc80 function may be relevant, but not necessary, for
somite formation and not determinant for subsequent somite
function maintenance; this is consistent with the abundance of
pathways regulating this process and the complexity of positive
and negative feedback loops involved (Mara and Holley, 2007).
In support of the hypothesis of Ccdc80 secretion by the
notochord, we demonstrated its interaction with theHedgehog
pathway. Expression of ccdc80 resulted directly regulated by
the levels of Shh protein, and the opposite phenomenon was
never observed. These ﬁndings strongly indicate ccdc80 as a
down-stream effector of shh: its expression in the notochord is
promoted by shh, and the protein is likely released in the
surrounding tissues, contributing to somitogenesis. Thereafter,
we identiﬁed gadd45b2 as a potential ccdc80-target in this
process. gadd45b genes in zebraﬁsh are expressed in the PSM
and in the somites, they are regulated by the segmentation
clock and are ﬁne tuned in somite boundary formation
(Kawahara et al., 2005). In mammals and in zebraﬁsh, GADD45
proteins are involved in cell-cycle control, interacting with
MTK1/MEKK4 factors that are required for somite segmen-
tation (Mita et al., 2002; Kawahara et al., 2005). In addition,
Gadd45 family members were found to be involved in genome
demethylation in zebraﬁsh (Rai et al., 2008), suggesting an
important role for these factors in muscle development.
Indeed, the transcription activity of MYOD and MEF2 is
epigenetically regulated by histone methyltransferases (HMTs),
histone deacetylases (HDACs) and histone acetyltransferases
(HATs) (Caretti et al., 2004; Sartorelli and Caretti, 2005;
Mal, 2006) and changes in the methylation status of the human
MYOD CpG island might lead to oncogenic transformations
(Rideout et al., 1994).
Interestingly, the knock-down of gadd45b2 (Kawahara
et al., 2005) causes the same defects as ccdc80 knock-down and
the injection of gadd45b2 mRNA partially rescued the ccdc80-
loss-of-function phenotype, indicating its down-stream posi-
tion in the ccdc80 pathway.
This study demonstrates for the ﬁrst time the expression of
ccdc80 in notochord during zebraﬁsh development and its role
in somite formation and patterning. Moreover, our data
identify ccdc80 as a down-stream effector of the notochord
Hedgehog signaling and an up-stream regulator of gadd45b2 in
somite formation.
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Supplementary material 
Suppl. Figure 1: ClustalW2 alignment of CCDC8 homologous. Color legend: red, small, 
hydrophobic, and aromatic (-Y) residues; Blue, Acidic residues; Magenta, Basic residues; Green, 
Hydroxyl, Amine, Basic (-Q) residues. Consensus symbols: "*" identical residues in all sequences; ":" 
conserved substitutions; ".“ semi-conserved substitutions. 
 
Suppl. Figure 2: ccdc80 expression in early developmental stages. Diffuse ccdc80 expression at 1 cell 
(A), 4 cells (B), 1000 cells (C) and 30% epiboly (D). Scale bar indicated 250 m. 
 
Suppl. Figure 3: critical markers for gastrulation and convergence and axis formation are not 
affected in ccdc80-MO injected embryos. (A-B) gsc, marker of epiboly, resulted correctly expressed at 
shield stage in ccdc80-MO injected embryos. (C-D) Also the expression pattern of ntla, marker of the 
notochord, resulted unaltered in all embryos during somitogenesis. (E-F) shh expression was not 
perturbed by the ccdc80-MO injected embryos in comparison to controls. (A-B) Lateral views, dorsal to 
the right. (C-F) Dorsal views, rostral to the left. Scale bar indicated 100 m. 
 
Suppl. Figure 4: Rescue the ccdc80-loss-of-function phenotype with the co-injection of gadd452 
full-length-mRNA. myod expression in controls (A-A’), ccdc80-MO (B-B’) and ccdc80-
MO+gadd452mRNA-injected embryos at 8-10 s stage. (A-B-C) Lateral views, rostral to the left. (A’-
B’-C’) Dorsal views, rostral to the left. Scale bar indicated 100m. 
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